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6Abstract
The complement (C) system is part of the innate immune system in the first
line of defense. It consists of over 30 soluble or membrane-bound
components. The complement system can become activated through three
different (the lectin, the classical and the alternative) pathways, and the
activation is tightly regulated. The main functions of complement are to
defend us against invaders, e. g. microbes, and to remove immune
complexes, cell debris and apoptotic cells from the body. In the
antimicrobial defense, C activation may lead to opsonization or lysis of the
target, enhanced inflammatory reaction and recruitment of inflammatory
cells.
Despite the antimicrobial activities of complement, pathogenic microbes
have developed mechanisms whereby they can evade C attack. How do they
do this? This question has been addressed in this work by analyzing the C
evasion mechanisms of the important pathogens Streptococcus pneumoniae
(pneumococcus), Streptococcus agalactiae (group B streptococci, GBS) and
Neisseria meningitidis (meningococcus). The focus was on factors that
regulate the activities of complement C3 convertases on the surface of
bacteria. C3 convertases are central elements in C activation. Thus, their
inhibition is a key feature that makes these bacteria virulent.
C-reactive protein (CRP) was first identified by its ability to bind to the C-
polysaccharide of pneumococci. It is the prototype acute phase protein,
whose level increases during infection and tissue damage. In the present
study it was found that CRP binds factor H, a fluid-phase inhibitor of the
alternative pathway C3 convertase (I). CRP binds to two sites in the middle
region of factor H, thereby leaving the functional activity of factor H intact.
The results suggest that CRP can target factor H to areas of tissue damage to
suppress unnecessary inflammatory reaction (I, II). On the other hand, CRP-
mediated binding of factor H could help pneumococci to evade C attack.
Pneumococci cause respiratory infections, meningitis and sepsis. GBS cause
neonatal sepsis and skin infections in adults. Some strains of pneumococci
and GBS express surface proteins that bind factor H. These proteins,
pneumococcal Hic and B streptococcal β protein, were both found to bind to
7two similar sites in the middle region of factor H (II, III). The middle part of
factor H, by binding to CRP, pneumococci and GBS, thus turned out to be a
new functional region on factor H (I, II, III). Previously, there were no
known ligands for this area of factor H. Pneumococci and GBS, via Hic and
β,  can directly acquire factor H to their surfaces. The results showed that
surface-bound factor H remained functionally active and inhibited the
alternative pathway C3 convertase. Hic and β protein, although from two
different bacterial species, showed remarkable structural similarity and their
binding sites on factor H overlapped. This suggests that the expression of
these proteins is an analogous virulence mechanism that has been conserved
through evolution of these two bacterial species, pneumococci and group B
streptococci.
Serogroup B meningococci are gram-negative bacteria that cause meningitis
and sepsis. They were found to regulate the classical pathway C3 convertase
activity by binding another soluble C3 convertase regulator, the C4b-binding
protein (C4bp) (IV). Binding was dependent on the expression of the PorA
surface protein. By binding C4bp the meningococci were able to promote
inactivation of C4b and inhibit the classical C pathway. Thus, while
pneumococci and GBS evade the alternative pathway of C by binding factor
H, meningococci protect themselves against C attack by acquiring the
classical pathway inhibitor C4bp to their surface. Since C4bp is usually in
tight complex with the anticoagulant protein S, meningococci may also
indirectly influence blood coagulation via C4bp binding.
In summary, in this study the mechanisms whereby three important
pathogenic bacteria evade C3 convertase activity and complement attack
have been analyzed. Pneumococci, GBS and meningococci are pathogens
that cause pneumonia, meningitis and sepsis and are responsible for
significant morbidity and mortality worldwide. They express specific
proteins with which they bind host complement regulators to their surfaces.
These proteins (Hic, β and PorA) apparently are important virulence factors
and could be exploited in the development of vaccines. An ideal vaccine
could raise antibodies that not only bind to the microbes but also neutralize
their complement evasion molecules.
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9Abbreviations
AP Alternative pathway of complement
BSA Bovine serum albumin
C Complement
C1-INH C1-inhibitor
C4bp C4b-binding protein
CCP Complement control protein unit
CP Classical pathway of complement
CR1 Complement receptor 1
CR3 Complement receptor 3
CRP C-reactive protein
DAF Decay-accelerating factor
ELISA Enzyme-linked immunoadsorbent assay
FACS Fluorescence-activated cell sorter
Fc Crystallizable part of immunoglobulins
FH Factor H
FHL-1 Factor H-like protein 1
FHR Factor H-related protein
GAS Group A streptococcus, S. pyogenes
GBS Group B streptococcus, S. agalactiae
GPI Glycosyl phosphatidyl inositol
Ig Immunoglobulin
IL Interleukin
Hic Factor H-binding inhibitor of complement
kDa kilodalton
LNnT Lacto-N-neotetraose
LOS Lipo-oligosaccharide
MAC Membrane attack complex
MASP MBL-associated serine protease
MBL Mannose binding lectin
MCP Membrane cofactor protein
OMV Outer membrane vesicle
Opa Opacity protein
PorA Porin A
PorB Porin B
Psp Pneumococcal surface protein
PTX3 Pentraxin 3
SAP Serum amyloid P component
SCR Short consensus repeat
SDS-PAGE Sodium-dodecyl sulphate polyacrylamide gel electrophoresis
TNF Tumor necrosis factor
VR Variable region
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Introduction
The complement (C) system is an essential part of the innate immune system
in the first line of defense. Its functions include opsonization and lysis of
microbes, attraction and activation of leukocytes and enhancement of the
inflammatory response. In addition to acting independently, it also is an
important effector arm for the adaptive immune system. With all its
activities, complement also serves as a clean-up or waste-disposal system in
the removal of immune complexes, chromatin, apoptotic cells and cell
debris.
Microbes have survived on earth for over 3 billion years. Since the
emergence of animal hosts, the microbes have had a long time to develop
ways to evade the immune defense mechanisms of the potential hosts.
Pathogenic bacteria have also developed specific mechanisms to evade
complement. Although bacteria and the C system have been known for over
a hundred years, it is only relatively recently that the roles of C evasion
mechanisms in bacterial virulence have been addressed.
Some microbes are disguised with a capsule or lipopolysaccharide structures
resembling host surfaces, and some express proteases that cleave C
components. For many bacteria the C evasion mechanisms are still unknown.
The purpose of this study was to examine the complement evasion
mechanisms of three pathogenic bacterial species, Streptococcus
pneumoniae, Streptococcus agalactiae and Neisseria meningitidis. These
bacteria cause some of the most severe infections like pneumonia, sepsis and
meningitis. Complement evasion mechanisms affect directly the virulence of
the microbe. Thus, by identifying factors whereby a particular microbe
evades complement, it is possible to understand better how the microbe
causes disease and how this could be prevented.
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Literature review
The complement system
The complement system (C) is part of the innate immune system and
consists of over 30 soluble or membrane-bound proteins (Table 1).
Complement acts in the defense against microbes and other invaders and, on
the other hand, in the removal of immune complexes and apoptotic or
damaged cells, i.e. in the clean-up of the body.
Complement is activated through three different cascade-like pathways, (i)
the classical pathway (CP), (ii) the alternative pathway (AP) and (iii) the
lectin pathway. All three pathways converge at the C3 level and activation
continues through the terminal pathway.
The classical pathway
When antibodies bind to their target with a sufficient density they can initiate
activation of the CP. The first component in the CP, C1q is a complex 460
kDa molecule consisting of six subunits, each of which is comprised of 3
structurally related polypeptide chains (A, B and C) (53). C1q circulates in
complex with two C1r and two C1s molecules (C1qr2s2) (193). The globular
heads of the six subunits bind to the Fc part of IgG or IgM. Other activators
of CP include C-reactive protein (CRP), nucleic acids and damaged cell
membranes (61, 159, 227, 325). The binding of C1q to multiple IgG
molecules or to surface-bound IgM results in a conformational change in
C1q. This leads to proteolytic activation of C1r, which then, also
proteolytically, activates C1s. C1s is the active enzyme in the C1qr2s2
complex, which cleaves C4 and C2 (Fig. 1).
C4 consists of three chains which are held together by disulphide bonds
(280). C1s in the activated C1 complex cleaves C4 at a single site in the α-
chain. This leads to the release of a small C4a fragment and the disruption of
an internal thioester in the C4b polypeptide. Subsequently, C4b can bind
covalently to amino or hydroxyl groups on nearby surfaces (78, 187).
However, the exposed thioester site is labile and quickly inactivated by
hydrolysis if no target is available. Thus, C4b can only be deposited in the
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immediate vicinity of the C1 complex. Membrane-bound C4b is a receptor
for C2, a single-chain plasma molecule. C2 is bound to C4b and cleaved by
C1s to C2a, which remains bound to C4b, and to a smaller fragment C2b
which is released from the complex (222, 223). C4b2a constitutes the CP C3
convertase (63).
The next component in the cascade is C3, which is composed of two chains,
α and β, held together by disulphide bonds (221, 296). C3 is the most
abundant C protein in plasma. Its concentration is 1-2 mg/ml and half of it is
turned over daily. C3 is cleaved by C2a of the C4b2a complex at a single site
on the α-chain. This cleavage leads to the release of the C3a fragment and
the exposure of a thioester on the remaining C3b fragment. Upon disruption
of the thioester, C3b can bind covalently to a target surface. When C3b binds
to the C4b2a complex, the CP C5 convertase C3b4b2a is formed (168, 299).
Figure 1. Complement activation pathways. The regulators of complement
are boxed. Enzymatic activity is indicated by broken arrows. Abbreviations:
C1-INH, C1-inhibitor; MBL, mannose binding lectin; DAF, decay
accelerating factor (CD55); C4bp, C4b binding protein;  P, properdin; CR1,
complement receptor 1 (CD35); FH, factor H; I, factor I; D, factor D; B,
factor B; MCP, membrane cofactor protein (CD46); MAC, membrane attack
complex; SC5b-9, soluble terminal complement complex.
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Table 1. Components of the complement activation pathways.
Component    MW     Serum conc. Function
  (kDa)        (µg/ml)
Classical pathway
C1q 460 80 Binds to IgG and IgM,
   initiates CP activation
C1r 83 50 Cleaves and activates C1s
C1s 83 50 Cleaves and activates C4 and C2
C4 205 600 C4b binds C2 and forms CP
   C3 convertase with C2a
C2 102 20 C2a forms CP C3 convertase with C4b, 
   cleaves and activates C3 and C5
Alternative pathway
Factor B 93 210 Bb forms AP C3 convertase with C3b,
   cleaves and activates C3 and C5
Factor D 24 2 Cleaves and activates factor B
Lectin pathway
MBL 96 x 2-6 0-5 Binds to carbohydrates on
   microbial surfaces, initiates the
   lectin pathway
MASP-1 83 Cleaves and activates C3
MASP-2 76 Cleaves and activates C4 and C2
Common
C3 185 1300 C3b forms the AP C3 convertase with Bb,
   forms the CP and AP C5 convertases
   with C4b2a and C3bBb
Terminal pathway
C5 190 70 C5b is part of MAC
   C5a is chemotactic and anaphylatoxic
C6 120 65 Part of MAC
C7 110 55 Part of MAC
C8 150 55 Part of MAC
C9 69 60 Part of MAC
Abbreviations: MW, molecular weight; kDa, kilodalton; conc.,
concentration; CP, classical pathway; AP, alternative pathway; MBL,
mannose binding lectin; MASP, mannose binding lectin-associated serine
protease; MAC, membrane attack complex.
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The alternative pathway
C3 is a central component also in AP activation. C3 is constantly hydrolyzed
in the fluid-phase at a slow rate to form C3(H2O) (181). C3(H2O) binds
factor B, a single-chain AP analogue of C2. Factor B, once bound to
C3(H2O) is cleaved by factor D (189, 190). Factor D is a serine protease,
which cleaves factor B to a larger Bb fragment and a smaller Ba fragment
that is released into the fluid phase. The formed C3(H2O)Bb complex is a
fluid phase C3 convertase, where the serine protease Bb cleaves C3 to C3b
which can deposit on nearby surfaces. This constant low-level deposition of
C3b on surfaces is called the tick-over phenomenon of the AP (181, 231).
Subsequently, factor B binds to the deposited C3b on the surfaces. After
cleavage by factor D, the resulting AP C3/C5 convertase C3bBb cleaves
further C3 molecules.
The activation of AP augments also activation initiated by CP. This occurs
after CP activation leads to the deposition of C3b on surfaces. C3b
molecules are capable of binding factor B, which is then susceptible to
cleavage by factor D. Thus, CP activation is amplified by the activation of
AP. Therefore, the C3b-Bb-factor D circle is called the amplification loop.
Even when activation is initiated through CP, the AP amplification loop
needs to be recruited to ensure efficient C activation.
The lectin pathway
Mannose binding lectin (MBL) is a large molecule resembling C1q in
structure. Its serum levels (≈ 1 µg/ml), however, are only 1/100th of those of
C1q (108). MBL binds to polysaccharides rich in mannose and N-
acetylglucosamine residues, which are present on some microbial cells.
MBL is associated with two serine proteases, MBL-associated serine
protease –1 and –2 (MASP-1 and -2) (275, 303). The surface-bound MBL-
MASP-complex cleaves C4 and C2 and the activation of C continues as
described above for CP.
The terminal pathway
C5 is a two-chain plasma protein which is cleaved by the C3b4b2a complex
to a larger C5b fragment and and a smaller C5a, a powerful chemotactic and
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anaphylatoxic agent (234, 324, 332). Analogously, C5 can be cleaved by the
AP C5 convertase complex, C3bBbC3b. Regardless of whether C5 becomes
cleaved by the CP or AP C5 convertase, the cleavage results in the exposure
of a C6-binding site on C5b and initiation of membrane attack complex
(MAC) formation.
C5b-6 complexes bind C7, the next C component. The binding of C7 results
in a conformational change in the C5b67 complex, which is capable of
inserting into nearby cell membranes (77, 183). The C8 component binds C7
in the complex, which then becomes more deeply buried in the target cell
membrane (300).
C9 binds to the C5b-8 complex. This results in a conformational change in
C9, which will enable it to traverse the membrane. At the same time, binding
sites for additional C9 molecules are exposed on the C5b-9 complex. As
more C9 molecules bind to the C5b-9 complex, a pore causing membrane
leakiness is formed (311, 312). The MAC is the endpoint of C activation. It
can cause osmotic lysis of the target cell or lead to various other effects, like
cell activation because of calcium influx.
Regulators of complement
As complement can cause significant tissue damage, its activation must be
kept in tight control. Both soluble and membrane-bound regulators keep C
activation under control and protect self cells from unwanted consequences
of C activation (Table 2).
Soluble regulators
C1-inhibitor
C1-inhibitor (C1-INH) is a soluble regulator of the CP. It is a single-chain,
105 kDa glycoprotein that belongs to the family of serine protease inhibitors
(serpins), which share structural and functional properties (55, 128). The
target specificities of these inhibitors are determined by amino acids at and
close to the reactive center, which binds to the target proteases, i.e. C1r and
C1s in the case of C1-INH. C1-INH is cleaved by the protease activities of
C1r and C1s but remains tightly bound to the complex, thereby rendering the
complex inactive (Fig. 1, Table 2).
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C1-INH is also a biologically significant inhibitor of kallikrein and
coagulation factor XII (71, 112). In addition, C1-INH inhibits plasmin and
coagulation factor XIa (101, 127). C1-INH can also inhibit the MBL-
associated serine proteases MASP-1 and MASP-2 (200). The inherited
deficiency of functional C1-INH causes hereditary angioedema, a rare
disease characterized by transient, recurrent attacks of cutaneous and
mucosal edema. Even though the disease usually has a mild course, it is
potentially life-threatening in case of laryngeal edema and consequent
suffocation.
Table 2. Soluble and membrane-bound regulators of complement
Component  MW     Serum conc. Function
   (kDa)       (µg/ml)
Soluble regulators
C1-INH 105 200 Binds and inactivates C1r and C1s
C4bp 540-590 250 Accelerates decay and inhibits
   formation of CP C3 convertase,
   cofactor for factor I
Factor H 150 500 Accelerates decay and inhibits
   formation of AP C3 convertase,
   cofactor for factor I
Factor I 90 35 Cleaves and inactivates C3b and
    C4b in the presence of a cofactor
Properdin 220 26 Stabilizes AP C3-convertase
S protein 80 500 Prevents MAC formation
Clusterin 70-80 50 Prevents MAC formation
Membrane-bound regulators
DAF (CD55) 70 Accelerates decay of AP and CP
   C3- and C5-convertases
MCP (CD46) 51-68 Cofactor for factor I
CR1 (CD35) 190-220 Accelerates decay of AP and CP
   C3- and C5-convertases,
   cofactor for factor I
Protectin (CD59) 18-23 Prevents MAC formation
Abbreviations: MW, molecular weight; kDa, kilodalton; conc.,
concentration; C1-INH, C1-inhibitor; C4bp, C4b-binding protein; CP,
classical pathway; AP, alternative pathway; MAC, membrane attack
complex.
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C4b-binding protein
C4b-binding protein (C4bp) is a 540-590 kDa multi-chain regulator of the
CP. C4bp usually consists of 7 α-chains (70 kDa) and one β-chain (45 kDa)
(59, 140, 277). The chains are linked together by a central core (Fig. 2). The
α-chains are composed of 8 and β-chains of 3 short consensus repeat (SCR;
also called complement control protein repeat, CCP) units. Each SCR has
appr. 60 amino acids held together in a domain structure by two internal
disulphide bridges (149, 169).
C4bp regulates the activation of CP by preventing the assembly of the CP
C3-convertase C4b2a and accelerating the decay of this complex by
promoting dissociation of C2a from C4b (decay acceleration activity). It also
acts as a cofactor for factor I in the cleavage of C4b (cofactor activity) (Fig.
1, Table 2) (104, 111, 224). The C4b binding sites on C4bp have been
located to the N-terminal SCRs 1-3 of the α-chains (Fig. 2) (37). C4bp also
binds heparin with a relatively high affinity, and the heparin binding sites
have been mapped to the same SCRs 1-3 of the α-chains (37, 138). The
C4bp-C4b interaction can be inhibited by heparin (138). Serum amyloid P
component (SAP) binds to the central core (282). Some reports state that this
interaction inhibits the C regulatory activities of C4bp, while other
investigators have found no interference (107, 282).
Figure 2. Schematic structure of C4bp. The binding sites (SCR1-3) for C4b
and heparin are marked on one α-chain. SAP, serum amyloid P component;
SCR, short consensus repeat.
In circulation, 50% of C4bp is in complex with protein S, an anticoagulant
protein. In regulating the coagulation cascade, activated protein C requires
α-chains
binding site for C4b and heparinSCR1
β-chain
binding site for SAP
binding site for protein S
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protein S as a cofactor for its anticoagulant functions (330, 331). Protein S
binds very strongly to CCP1 of the C4bp β-chain (131, 132). C4bp-bound
protein S is functionally inactive (66). Appr. 70% of protein S is in complex
with C4bp and only 30% remains free (and active) (67-69). On the other
hand, protein S does not interfere with the C regulatory functions of C4bp.
Factor H
Factor H (FH) is a fluid-phase regulator of the AP amplification loop. It is a
soluble 150 kDa protein composed of 20 SCR domains (Fig. 3) (233, 359).
FH regulates the AP by inhibiting the binding of factor B to C3b, acting as a
cofactor for factor I-mediated cleavage of C3b (cofactor activity) and
accelerating the decay of the AP convertase C3bBb (decay-accelerating
activity) (243, 335, 343). All these steps are essential in keeping the AP
amplification loop under control. By controlling the key steps of the
amplification loop FH inhibits also activation that has been initiated via the
classical or the lectin pathway.
The cofactor and decay-accelerating activities of FH have been located to the
SCR domains 1-4 (117, 178, 179). FH has three binding sites for C3b, the
first at the N-terminal SCRs 1-4, the second in the middle part of FH at
SCRs 12-14 and the third at the most C-terminal SCRs 19-20 (160, 162,
284). FH has also three binding sites for heparin, at SCR7, around SCR13
and at SCR20 (Fig.3) (34, 35, 211, 241). These heparin binding sites
correlate with the binding of FH to polyanions, like glycosaminoglycans and
sialic acids.
In addition to controlling the AP activation in the fluid phase, FH has an
important function in discrimination between AP activating and
nonactivating surfaces. As C3 undergoes spontaneously low level hydrolysis
to produce C3(H2O) that can bind factor B (tick-over), the AP is in a
continuous state of alertness to react with target structures (181). Upon
contact with a surface the default for AP is to become activated, unless
inhibited. As a consequence, C3b molecules get constantly deposited on
nearby surfaces. Surfaces of intact human cells (“nonactivators”) are
abundant in terminal sialic acids and glycosaminoglycans. As FH has a high
affinity for C3b when the surface around C3b is coated with these
polyanions, AP activation is kept under control (91, 166, 211, 242).
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However, if the surface is devoid of polyanions, the affinity of FH for
surface-associated C3b is reduced and C activation proceeds.
Following tissue damage because e.g. of infection, inflammation or
ischemia, the structural integrity of cell membranes breaks down and
different types of structures like certain phospholipids, cytoskeletal
components and nuclear chromatin become exposed. Many of these
structures activate the CP. As the emerging structures may lead to
unrestricted activation of C, there is a need to suppress excessive AP
amplification. At the same time, however, the clearance of nonviable
structures should occur in a well-regulated and focused manner. At present,
we only partially understand how this important process is orchestrated.
Figure 3. Factor H protein family. All members consist exclusively of SCR
domains. The individual domains are aligned according to the highest
homology. Heparin binding sites are marked on FH, FHL-1 and FHR-3.
FHR-1 and -5 also bind heparin but the heparin-binding domain has not been
established yet. FHL-1, factor H-like protein 1; FHR, factor H-related
protein.
Factor H protein family
Factor H is a member of a family of proteins that also contains factor H-like
protein 1 (FHL-1) and factor H-related proteins 1-5 (FHR-1-5) (Fig. 3) (205,
359). FHL-1 is an alternatively spliced product of the FH gene. FHL-1
consists of the seven most N-terminal SCR-domains of FH and four unique
amino acids at the C-terminal end (360). The plasma concentration of FHL-1
Factor H     
FHL-1   
74 2 0
71   2   3   
1 1 32 3 5 6 8 9 1 1 1 2 1 4 1 5 1 6 1 7 1 8 1 91 0
Heparin binding site
FHR-1   
FHR-2   
FHR-3   
FHR-4   
FHR-5   1 2
4   5   6
1    2      3   4   5
1    2      3   4   
1   2   3   
1         2   3   
4   5   
4   5  
3  4    5  6   7 8   9
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is only 10-50 µg/ml, i.e. about 2-10 % of that of FH. FHL-1 has decay-
accelerating and cofactor activities, which suggests that FHL-1 has C
regulatory activity in vivo (178, 179). FHRs are encoded for by separate
genes located in the “regulators of complement activation” (RCA) gene
cluster on chromosome 1, band 1q32. To date, 5 FHRs  have been identified.
All of these are exclusively composed of SCR domains and bear striking
structural similarity to each other and FH (359). Despite the fact that FHRs
all are known to bind C3d part of C3b with their two most C-terminal
domains, their functions are still unknown (134, 135).
Factor I
Factor I is a soluble 90 kDa protein that consists of two chains, the heavy (50
kDa) and the light (38 kDa) chain (182, 270). Factor I cleaves C3b and C4b
in the presence of a cofactor. The cofactor  can be either C4bp, factor H,
membrane cofactor protein (MCP) or complement receptor type 1 (CR1).
The function of factor I is essential in the regulation of C activation. The
deficiency of factor I is very rare, only a few dozen cases have been
described in the literature (328). Analysis of patients with factor I deficiency
has provided important insight into the activities of the AP (2, 358). Factor I
deficiency leads to a secondary deficiency of C3 and susceptiblity to
recurrent pyogenic infections.
Other soluble regulators
Properdin is the only known physiological positive regulator of C. Properdin
stabilizes the C3bBb complex of the AP. Binding of properdin to the
complex extends its half-life 3-4 –fold (93). Properdin circulates in plasma
as oligomers of 2-4 53 kDa polypeptides (286).
Two soluble inhibitors of the terminal C pathway have been described.
Clusterin (SP40,40, apolipoprotein J) is a multifunctional 70-80 kDa
glycoprotein, which consists of disulphide-linked α- and β-chains (156).
Clusterin was first recognized by its ability to aggregate Sertoli cells (36).
Later, it was recognized as a C inhibitor. It binds to the terminal C5b67 and
C5b678 complexes and prevents their insertion into cell membranes (310). S
protein (vitronectin, cell-spreading factor) is an 80 kDa protein composed of
two disulphide-linked chains (249). One form of S protein mediates cell
attachment in tissues (19). In the C system, soluble S protein binds to the
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fluid-phase C5b67 complex, and keeps it in the fluid phase similarly as
clusterin (249).
Membrane-bound regulators
To date, four membrane-bound regulators of C have been identified in man
(Table 2). Three of these inhibit the C3 and C5 convertases and one
(protectin) inhibits formation of the MAC.
Membrane cofactor protein (MCP, CD46)
Membrane cofactor protein is a 51-68 kDa integral membrane glycoprotein.
It is present on nearly all cell types except erythrocytes. MCP contains 4
SCR domains, a transmembrane region and a cytoplasmic tail (194). MCP
binds to C3b and C4b and acts as a cofactor for factor I-mediated cleavage of
both proteins (283).
Decay accelerating factor (DAF, CD55)
Decay accelerating factor  is a 70 kDa membrane glycoprotein. It consists of
4 SCR domains and is anchored to the cell-membrane via a
glycophosphoinositol (GPI) anchor (207, 208). DAF binds to and dissociates
both the CP (C4b2a) and AP (C3bBb) C3/C5 convertases (230).
Complement receptor 1 (CR1, CD35)
Complement receptor 1 is a receptor for C3b and C4b (92). It is a long
membrane glycoprotein that exists in two major allelic froms of 190 and 220
kDa. CR1 consists of 30 SCR units and has three binding sites for C3b
and/or C4b (172, 173). Multiple binding sites allow multivalent interactions
with immune complexes containing several C3b and C4b molecules. CR1
acts as a cofactor for the factor I-mediated cleavage of C3b and C4b (148,
206). It also accelerates the decay of the AP and CP C3/C5 convertases,
C3bBb and C4b2a, respectively.
CD59 (protectin)
Protectin is another GPI-anchored C regulator (293). It is a glycosylated
membrane protein with an apparent mass of 18-23 kDa. Protectin is present
on practically all cell surfaces. It inhibits the assembly of MAC by binding to
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terminal C complex-associated C8 and C9 and preventing C9 incorporation
and polymerization (210, 263). Protectin can become released from the cell
surface. When detached from its lipid anchor by a phospholipase, protectin is
converted into a soluble form (209).
Functions of complement
Complement has functions both in the defense against microbes and, on the
other hand, in the clean-up of tissues. Complement activation leads to
deposition of C4b and C3b and their inactivation products on the target
surface. Phagocytes have receptors for C3b and C4b (CR1) and iC3b (CR3
and CR4) (94, 269). The recognition of these opsonins by the phagocytic
cells enhances phagocytosis. The soluble cleavage products C3a and C5a
released during C activation are powerful chemotactic agents and
anaphylatoxins (332). Thus, an inflammatory response is generated at the
site of C activation. This also promotes removal of the intruding microbes.
Terminal pathway activation leads to the formation of MAC on the target
surface. This is important in the defense against gram-negative microbes. In
gram-positive organisms the peptidoglycan effectively inhibits the formation
of MAC. The formation of MAC is especially important in the killing of
Neisseriae. This is underlined by the fact that individuals deficient in the late
components of C are susceptible to recurrent neisserial infections.
Recently, it was found that C3d acts as a powerful natural adjuvant in the
antigen presentation to B cells (73). Antigens become coated with C3b
which is eventually cleaved into iC3b and C3d. Follicular dendritic cells and
B cells have receptors for C3b and C3d (CR1/CD35 and CR2/CD21). A
contact between the follicular dendritic cell-bound antigen-C3d complex and
the B cell coreceptor complex of CD21/CD19/CD81 leads to an enhanced B
cell response (232). Without the presence of C components, the antibody
response and the development of memory cells would be less efficient.
A very important function of complement is the solubilization and transport
of immune complexes (278). The CP gets activated on immune complexes
and this leads to the deposition of C4b and C3b on the complexes. The
binding of C proteins inhibits the formation of large complexes and also
makes them more soluble. C4b and C3b are recognized and bound by CR1
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on erythrocytes, and the complexes get transported to the liver and spleen for
disposal.
Complement also has a role in the clearance of apoptotic cells. C1q binds
directly to surface blebs of apoptotic cells and CP gets activated until the
C3b level (176, 227, 228). C3b is inactivated to iC3b, which is bound by the
CR3 (CD11b/CD18) receptor on macrophages. The apoptotic cell becomes
phagocytosed. As C activation does not proceed to the C5 level, C5a, the
powerful chemotaxin and anaphylatoxin, is not released. Thus, the
inflammatory reaction remains controlled. Recent results also suggest a role
for C in the development of B cell tolerance against autoantigens. C4 and the
CR1 and CR2 receptors are thought to be involved in the negative selection
of self-reactive B cells (250).
Pentraxins – complement-interacting proteins
The complement system interacts with several plasma proteins, e.g. the
pentraxins. Pentraxins are a family of proteins with a characteristic
pentameric organization of identical subunits (110). The classical pentraxins
are C-reactive protein (CRP) and serum amyloid P component (SAP). CRP
consists of 5 monomers in a β-jelly roll topology while SAP has 10
monomers arranged in two layers (110). SAP has 60% amino acid homology
with CRP (175). The genes for both SAP and CRP are located in
chromosome 1 (288). CRP and SAP have been found in all mammalian
species studied so far and also in many invertebrates. Their structures have
remained conserved during evolution and no deficiencies are known (248).
In humans, monkeys, dogs and rabbits CRP is an acute phase protein
whereas SAP is constitutively expressed. In contrast, in mice SAP is an acute
phase reactant and CRP is constitutively expressed (175, 248).
In recent years, new, so-called long pentraxins have been identified. The best
known of these is pentraxin 3 (PTX3) (43, 188). Long pentraxins are
structurally related to the short pentraxins SAP and CRP. PTX3 has a C-
terminal pentraxin-like domain and an N-terminal portion which is not
related to CRP or SAP (43). Common functional features of all three
pentraxins include the binding of C1q and the ability to activate the CP (61,
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225, 353). It has also been postulated that pentraxins have a role in the
removal of apoptotic cells (87, 109, 226).
C-reactive protein (CRP)
C-reactive protein is the prototype acute phase protein. Its serum level is
usually below 1 µg/ml but during inflammation or extensive tissue damage it
may rise up to 500 µg/ml within 24 hours due to increased synthesis in liver
(60, 248). CRP production is stimulated by IL-1 and IL-6 and quickly
subsides once the triggering factor has been eliminated (21). Measurement of
CRP is widely used in clinical practice to assess the severity and extent of
infection, inflammation and tissue damage (105, 154).
CRP was initially identified and named by its capacity to bind to and
precipitate the C-polysaccharide of Streptococcus pneumoniae
(pneumococcus) (1, 304). Later, the binding ligand on the pneumococcal C-
polysaccharide was found to be phosphorylcholine (326). Several other
ligands for CRP have been recognized during the last decades. The binding
of CRP to its ligands is dependent on the presence of calcium (1, 175). CRP
has two calcium-binding sites on each of its monomers. CRP has been
shown to bind to e.g. chromatin, DNA, nucleosomes, histones, cell debris
and FcγRII receptors on macrophages (30, 80, 260, 261, 289, 351).
One of the first CRP ligands identified was phosphorylcholine present on
damaged or apoptotic cell membranes (261, 327). This ligand is normally
not accessible on the cell surface but becomes exposed after tissue injury.
CRP binds C1q and activates CP (61, 325, 344). However, C activation by
CRP does not lead to the formation of MAC. Instead C activation seems to
be stopped at the C3b level but the mechanism of this has not been known
(24).
Despite the fact that CRP-measurement is one of the most common
laboratory tests in medicine, the physiological function of CRP has remained
unknown. CRP binds to pneumococci and some other microbes, e.g.
Haemophilus influenzae and Leishmania donovani (65, 337). In animal
experiments CRP protects mice from pneumococcal infection (220, 295,
355). However, this can hardly be the main physiological role of CRP. A
more important function for CRP could be in the removal of apoptotic cells
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and cell debris (109). CRP binds to apoptotic cells and to cell material
exposed during cellular damage (e.g. chromatin and phospholipids) (261).
Complement and microbes
Microbes in general are susceptible to C attack. However, in order to be
pathogenic, an organism must survive in the host and evade the immune
system. Thus, many pathogenic microbes have evolved mechanisms to evade
C attack (90, 161, 256, 348).
The thick peptidoglycan layer of gram-positive bacteria is in general
protective against MAC formation and lysis. Therefore, activation of the
terminal pathway has a minor role in the defense against gram-positive
bacteria. Also the bacterial capsule and, and especially in gram-negative
organisms, the O-polysaccharide side chains of the lipopolysaccharides offer
steric hindrance against MAC formation.
Some microbes have been found to bind C regulators, e.g. factor H.
Microbes do not naturally produce glycosaminoglycans for FH to bind, but
they can have e.g. hyaluronic or sialic acid moieties. For example, serotype
III group B streptococci, group B meningococci and Escherichia coli K1
produce capsules that are composed of polysialic acid (17, 31, 164).
Although polymeric sialic acid does not seem to bind FH efficiently, the
capsules of these bacteria are thought to mediate C resistance via FH
binding. Specific resistance to the AP can also be mediated by surface
proteins that bind FH. Once FH is bound to the surface through these
molecules, C activation is restricted. E.g. the M-protein of group A
streptococcus (GAS, Streptococcus pyogenes) and the OspE-protein family
of serum-resistant strains of Borrelia burgdorferi bind FH from serum (136,
143). The FH-binding capacity is not restricted to bacteria as the yeast
Candida albicans and the nematode parasite Onchocerca volvulus have also
been shown to acquire FH to their surfaces (212, 213).
Microbes have also been shown to acquire the CP regulator C4bp to their
surfaces. At least group A streptococcal M-protein, N. gonorrhoeae and
Bordetella pertussis bind C4bp (23, 252, 302). In general, the binding of FH
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or C4bp may confer serum resistance to bacteria and prevent their
opsonophagocytosis.
Also the membrane-bound regulators of C are utilized by several microbes.
Helicobacter pylori and E. coli have been shown to acquire GPI-anchored
protectin (CD59) from human cells at the site of infection (255, 257). The
hijacked CD59 is incorporated into the bacterial cell membrane in a
functionally active form. Thus, the microbes are protected against C lysis. As
an example of C inhibitors that microbes produce themselves, trypanosomes
are capable of synthesizing a DAF-like inhibitor (T-DAF) of the CP or AP
C3/C5 convertases (235).
Some pox- and herpesviruses encode proteins with functional similarities to
human C regulators. E.g Herpes simplex –virus HSV-1 encodes the gC-1
protein that is not structurally homologous to human C inhibitors but
accelerates the decay of the AP C3 convertase and inhibits the binding of
properdin to C3b (103, 177). It thus resembles functionally CR1 and FH.
In addition to acquisition of CD59, H. pylori can avoid C activation by
expressing the urease enzyme which cleaves C3 (262). Also Pseudomonas
aeruginosa expresses proteases that cleave C1q and C3 (142). By cleaving
the chemotactic and anaphylatoxic C5a, microbes can restrict the developing
inflammatory reaction and the recruitment of inflammatory cells to the site
of infection. At least GAS, Entamoeba histolytica, Serratia marcescens and
group B streptococci (see below) have been shown to express a C5a
peptidase (38, 237, 258, 342).
Only some of the various microbial C evasion mechanisms have been
described above. The multiplicity of mechanisms becomes evident even
from these examples. However, despite the constantly accumulating
knowledge, the complement evasion mechanisms of pathogenic microbes are
still only partially known. Although some mechanisms how microbes avoid
C activation in vitro have been recognized, it is not known whether these
mechanisms have any functional significance for the microbial survival in
the human host. The C evasion molecules often represent microbial
virulence factors. Also, these factors represent putative vaccine targets.
Therefore, their recognition is important for attempts to prevent infections.
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Streptococcus pneumoniae
Streptococcus pneumoniae is a frequent colonizer of the nasopharynx both in
children and in adults. In small amounts, it is considered as part of the
normal upper respiratory tract flora. However, pneumococci cause upper and
lower respiratory tract infections, as well as invasive infections like sepsis,
meningitis and suppurative arthritis. Pneumococcus causes more deaths than
any other bacterium, and pneumococcal infections are the fifth leading cause
of mortality worldwide (163). The disease burden lies mostly on infants,
elderly people over 60 years of age and on the immunocompromised.
Pneumococci are divided into over 90 serotypes according to the structure of
their capsular polysaccharide (137). However, only about 20 serotypes are
frequently isolated in clinical samples (52, 119). There is considerable
variation in virulence among pneumococcal strains even with identical
capsular serotypes.
Figure 4. Schematic structure of the pneumococcal cell surface. Hic and
several other PspC (pneumococcal surface protein C) family proteins are
anchored to the cell wall via an LPXTG motif. PspA and several other
choline binding proteins are attached to the choline residues of lipoteichoic
acid (LTA) and C-polysaccharide (teichoic acid). The structure of the
capsular polysaccharide is the basis of pneumococcal serotype division.
The pneumococcal surface consists of several layers (Fig. 4). Innermost is
the cell membrane, followed by a few layers of peptidoglycan and the cell
wall polysaccharide (C-polysaccharide or teichoic acid) (305). The
polysaccharide capsule of virtually all virulent streptococci has a negative
C-polysaccharide
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXPeptidoglycan
Cytoplasmic
 membrane
   Capsular
polysaccharide
Hic/PspC
PspA
LTA
29
charge (155, 294). The C-polysaccharide and the lipoteichoic acid, that is
attached to the cell membrane, have an unusual structure including choline
(48, 307). Several surface proteins of pneumococci are attached
noncovalently via a choline binding  domain to the choline moiety (124, 264,
356). Some surface proteins are anchored to the cell wall through the
common gram-positive bacterial cell wall peptidoglycan attachment motif
(LPXTG) (147, 152). Many surface proteins have positively charged regions
that interact with the negatively charged capsule (155, 294). The capsule
itself is a loose structure and following complement activation C3b becomes
deposited both on the capsular surface and on the cell wall (146).
The virulence factors of pneumococci have been extensively studied for
decades and several factors have been shown to be involved. The capsule is a
prerequisite for virulence. Non-capsulated mutants have low virulence and
are quickly cleared from the circulation (333, 334). However, the main role
of the capsule in virulence is probably to protect pneumococci against
phagocytosis. Other factors significant for virulence or evasion of the host
defense include pneumococcal surface proteins A and C (PspA, PspC),
pneumococcal surface adhesin A (PsaA), pneumolysin and autolysins (e.g.
LytA) (25, 26, 28, 47, 49, 54).
Pneumococcal vaccines
Currently, the focus in pneumococcal vaccines is in capsular conjugate
vaccines with a protein carrier. They have proven out to be more
immunogenic than the polysaccharide vaccines (180, 246, 347). At present,
the first 7-valent conjugate vaccine with diphteria toxin as a carrier is in
clinical use in many countries and several conjugate vaccines are in clinical
trials (347). Conjugate vaccines are immunogenic in infants as well as in
adults but they are more expensive which limits the use in the developing
countries. Furthermore, the valency is limited and there have been signs that
the serotypes against which the vaccine is not directed become more
prevalent (236, 240). Another possibility is to use pneumococcal proteins as
vaccines or, more attractively, combinations of proteins and polysaccharides.
The latter could confer cross-protection against several serotypes.
Pneumococcal proteins that have been or are being tested in animal models
or in humans include pneumolysin, PspA, choline binding protein A (CbpA),
pneumococcal surface adhesin A (PsaA) and the PhpA protein (44-46, 238,
357). The hope is that antibodies developing against important virulence
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factors would neutralize them and promote immune clearance of the
pathogenic bacterium.
Complement and pneumococci
Both the classical and alternative pathway of C are important in defense
against pneumococcal infections (130, 144, 151). Terminal pathway
activation and the formation of the membrane attack complex are ineffective
against pneumococci because as gram-positive bacteria pneumococci lack an
outer membrane to which the MAC could insert. Individuals deficient in the
early components of CP or AP are susceptible to pneumococcal infections,
even to recurrent infections (96, 151). Antibody production against
pneumococci is compromised in patients lacking C3 (130). IgG2 appears to
be the most important antibody subclass in the humoral response to
pneumococcus. Patients deficient in IgG2, and IgA-deficient individuals who
have concomitantly impaired IgG2 responses, are at an increased risk for
pneumococcal infection (185, 272). This is probably based on the ability of
IgG2 to preferentially recognize carbohydrates.
The activation of AP is crucial for opsonophagocytosis and the clearance of
pneumococci. Tu et al. demonstrated the significance of AP by using mice
deficient in factor B, C3 or C5 (313). Natural infection and immunization
elicit a capsule-specific IgA-response. In the absence of complement, this
specific IgA could induce minimal bacterial uptake and killing by
phagocytes. AP activation was required for efficient phagocytosis.
Interestingly, polymeric (dimeric) IgA seems to be capable of activating
complement on the surface of pneumococci and participate in the
opsonophagocytosis (150). It has also been shown that the efficiency of
opsonization with C3 fragments depended on intact AP even though it was
initiated by the CP (350). In contrast, Brown et al. have demonstrated, using
knock-out mice, that both CP and AP are needed for the clearance of
pneumococci in mice but the CP is the dominant one (50). Studies in mice
have demonstrated that natural IgM-class antibodies play an important role
in activating the CP on pneumococci. Thus, it appears that in the defense
against pneumococci the CP is important in initiating complement activation,
whereas the AP determines the final amount of C3 deposition on the
bacteria.
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Complement evasion by pneumococci
As pathogens pneumococci need to protect themselves against C attack. The
capsule efficiently prevents MAC attack but multiple mechanisms are
needed to prevent opsonophagocytosis. In the following, some factors that
are presumed to influence C attack on pneumococci are descibed.
Pneumolysin
Pneumolysin is a 53 kDa intracellular protein expressed by all virulent
strains of pneumococci (62). It is cytotoxic to several cell types, e.g.
erythrocytes, leukocytes, endothelial cells and alveolar epithelial cells (62).
Pneumolysin also activates the CP even at sites distant from the organism
(247). This may lead to complement depletion and reduced serum opsonic
activity. CP activation has been suggested to be mediated through
pneumolysin’s capacity to bind to the Fc part of IgG (217). Pneumolysin is a
virulence factor for pneumococci, as mutant strains not expressing
pneumolysin are avirulent (27, 28). However, the virulence differences
between strains can not be attributed to differences in pneumolysin
production alone (22).
Pneumococcal factors affecting C3b degradation
Early studies have shown that pneumococcal strains with different capsular
types differ in the amounts and sites of bound C3b, as well as in the types
C3b degradation products generated (146). Cheng et al. showed that CbpA, a
choline-binding protein of the PspC family binds directly C3 (58). Later it
has been suggested that pneumococci can degrade both α and β chains of C3
in the absence of serum components (8). Hostetter has reported that two
pneumococcal proteins appear to have proteolytic activity against C3 (145).
Using sequences of these proteins it was recognized that one of them is a
fragment of a larger protein, which was cloned and named PhpA (357). A 79
kDa fragment of PhpA was used for immunization in mice and found to be
protective against several pneumococcal strains. However, the ultimate
function of this protein remains unclear, as it has not yet been confirmed that
this fragment of PhpA has proteolytic activity for C3.
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Pneumococcal surface protein A
Pneumococcal surface protein A (PspA) is a surface exposed protein that is
one of the most extensively studied pneumococcal surface antigens. PspA is
expressed by all clinically important pneumococcal serotypes (64). It
consists of a highly charged N-terminal α-helical coiled-coil domain, a
proline-rich region, a choline-binding domain and a 17 amino acid
hydrophobic C-terminal tail (354).
Although the specific mechanism of action of PspA is not known, it is
required for full virulence in mouse models of pneumococcal infection
(202). It has been suggested that PspA functions as a complement inhibitor.
Tu et al. showed that in mice deficient in C3 or factor B, PspA-negative
strains became fully virulent (313). In wild type or C5-deficient mice PspA-
negative strains were avirulent. PspA reduced the amount of C3b deposited
on pneumococci. This suggests that PspA affects the activation of the AP
and inhibits the formation and/or function of the AP C3 convertase (313).
This in turn would reduce the efficiency of complement receptor-mediated
clearance. The precise mechanism how PspA acts in this respect is not yet
known. Based on the results of Tu et al. it can not be excluded that PspA acts
through binding FH (313). However, Neeleman et al. have shown that
pneumococcal binding of FH is not dependent on the expression of PspA,
and at least on serotype 3 pneumococci the resistance to phagocytosis is not
dependent on PspA expression (229). It has also later been observed both by
FACS analysis and by surface plasmon resonance assays that PspA does not
bind FH (70, Hellwage et al., unpublished). Thus, the complement inhibitory
mechanism of PspA remains open.
Pneumococcal surface protein C
The pneumococcal surface protein C (PspC) -family is a group of relatively
polymorphic proteins. Originally, PspC was identified by its similarity to
PspA (49, 201). Later, Hammerschmidt et al. found an IgA-binding protein
SpsA, and Rosenow et al. isolated a choline-binding protein which they
named CbpA (choline-binding protein A) (124, 264). Sequence analyses
showed that these proteins are encoded by alleles of the same locus (49).
Other allelic forms have been named after their binding characteristics, e.g.
C3-binding protein and FH-binding inhibitor of complement (Hic) (58, 152).
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The pspC gene is present in 75-100% of pneumococcal strains (49, 147). The
lower estimate is at least partly due to the fact that the PspC proteins are so
polymorphic that they are not always recognized as part of the group.
Iannelli et al. sequenced the pspC locus of 43 pneumococcal strains (147).
According to their results each pneumococcal strain contains a pspC gene at
the same chromosomal location and each pneumococcal strain has a unique
sequence at the pspC locus (147). PspC proteins can be divided into 11
groups. Common features for all groups are an N-terminal signal peptide
followed by an α−helical region, a proline-rich region and a C-terminal
anchor. In groups 1-6, the protein is anchored to the cell wall by a choline
binding motif. Group 7-11 PspC proteins are not anchored via choline,
instead they have the LPXTG motif, the typical cell wall sorting signal of
gram-positive bacteria. The main N-terminal region is predicted to have an
α-helical structure and its size varies between 118-589 amino acids (147).
Eight structurally conserved domains could be recognized by amino acid
sequence comparison. It seems that these eight domains are building blocks
for the N-terminal variable region in all PspC-proteins. The proline-rich
region is similar within the groups and also resembles the proline-rich region
of PspA (147).
PspCs are the only pneumococcal proteins that have been shown to bind FH
directly. First, Janulczyk et al. used streptococcal M protein and yersinial
YadA protein nucleotide and amino acid sequences to find putative FH-
binding proteins in the pneumococcal genome (152). The highest scoring
homology was identified to an allele of the pspC locus. The protein encoded
by this gene was found to be the FH-binding protein on a serotype 3
pneumococcal strain and named as the factor H-binding inhibitor of
complement or Hic (152). Structurally, Hic differs from the previously
recognized PspC-proteins, which might explain why serotype 3 was
originally considered to be PspC-negative. In the new nomenclature
suggested by Iannelli Hic belongs to group 11 with two other serotype 3
PspC-proteins (147).
Hic is an ≈ 70 kDa protein that is anchored to the pneumococcal cell wall via
the LPXTG motif which resembles the cell wall binding motif of e.g. group
A streptococcal M-proteins (152). The FH-binding region on Hic has been
mapped to the N-terminal amino acids 39-261 (or 1-223 when the signal
peptide is omitted) (Fig. 5). There is no 3-dimensional model of Hic but
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computer predictions based on amino acid sequence suggest that the N-
terminal signal peptide is followed by an α-helical region, also responsible
for FH binding (152). The C-terminal part of Hic has the typical proline-rich
repeats of PspC proteins. In the case of Hic, there are 24 repeats of 11 amino
acids (152). The function of this region remains is unknown. In the C-
terminus, the cell-wall spanning part is followed by the LPSTGS sequence
by which Hic is anchored to the bacterial cell wall.
Figure 5. A schematic representation of the Hic protein. Factor H binding
region is located at the N-terminal half of the protein and followed by a
proline-rich region. S, signal peptide; C, C-terminal region.
The PspC-proteins have also other ligands than factor H. Originally, the
PspC protein named SpsA was found to bind secretory IgA (124). The IgA-
binding motif is a hexapeptide YRNYPT, present in the N-terminal part of
several PspCs (125, 147). As an exception, the motif was absent from PspCs
expressed by serotype 3 strains (147). Therefore, it seems that the ability to
bind IgA is a widespread and conserved characteristic within the PspC
family. Whether this type of IgA binding has anything to do with the ability
of pneumococcus-bound polymeric IgA to activate complement, remains to
be solved (150).
Streptococcus agalactiae
Group B beta-hemolytic streptococci (GBS, Streptococcus agalactiae) are the
leading cause of severe neonatal infections. GBS are currently divided into 9
serotypes (Ia, Ib, II-VIII) according to the structure of their capsular
polysaccharide. Protective antibodies are directed against the polysaccharide
capsule but they are not cross-protective against other serotypes (57).
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GBS are part of the normal vaginal flora in 15-35 % of women (14). The
neonate usually acquires the infection through perinatal transmission from the
mother’s genital tract. If the mother has serotype-specific IgG-antibodies,
these are transmitted via placenta to the fetus and have been shown to protect
the newborn from invasive disease (16). In the neonate the infection usually
presents with sepsis, pneumonia or meningitis (14). GBS also cause skin
infections, sepsis, meningitis and pneumonia in adults (79, 88).
GBS vaccines
Efficient GBS vaccines are needed to prevent neonatal morbidity and
mortality. As the protective capsular polysaccharide antibodies are
transmitted through the placenta, vaccination of the mother confers immunity
also to the newborn. Levels of maternal antibodies against GBS correlate
with the neonate’s immunity to infection (16). The first vaccines in clinical
trials were composed of capsular polysaccharides. However, polysaccharide
vaccines are not immunogenic enough, furthermore, they are not cross-
protective. To prevent invasive disease in the Western world, at least a
pentavalent (Ia, Ib, II, III and V) polysaccharide vaccine is needed (244).
Furthermore, the serotype prevalence varies between regions. Several carrier
proteins have been tried, including tetanus toxoid, the β protein and C5a-ase
(57, 184, 196, 339). Some of the conjugate vaccines are in clinical trials but
none is yet widely available. Also bivalent protein vaccines have been tested
in animal models (186).
Complement and GBS
The polysaccharide capsule of GBS prevents opsonophagocytosis. Type III
GBS are one of the most common isolates in invasive infections (14, 281).
The type III strains expressing an unusually large amount of capsular
polysaccharide have been associated with higher invasiveness (199). Already
over twenty years ago it was shown that the sialic-acid rich capsule of type
III GBS inhibits AP activation in adult sera deficient in type-specific
anticapsular antibodies (85). Later, it was observed that the sialic acid moiety
of the type III capsular polysaccharide was crucial in inhibiting AP activation
(84). Asialylation of the capsular polysaccharide led to the loss of virulence
of the mutant strain (340). Therefore, sialic acid in the capsule is a critical
factor in the pathogenicity of type III GBS. The sialic acid-rich capsule
36
prevents C3b deposition, presumably through the action of factor H (199).
Inhibition of AP activation can be overcome by specific antibodies, thus
resulting in the deposition of C3b on the bacterial surface and
opsonophagocytosis by  neutrophils (84, 85, 199).
Figure 6. Schematic structure of the group B streptococcal cell surface. The
β protein is anchored to the cell wall via an LPXTG motif common to many
gram-positive bacterial surface proteins. The group-specific cell wall
polysaccharide is attached to the peptidoglycan layer.
While the sialic acid content of the capsule correlates with the inhibition of
the AP activation and resistance to phagocytosis, the CP has been implicated
in the antibody-independent humoral defense against GBS. Both C4-deficient
and C3-deficient mice were susceptible to GBS infection suggesting that the
CP also has a role in opsonization even in the absence of specific antibodies
(338). Other studies have shown that GBS can directly activate the CP (15,
82). Butko et al. showed that C1q directly binds to GBS through the globular
head region and this binding is not dependent on the polysaccharide capsule
(51). Binding of C1q by itself was not sufficient to promote
opsonophagocytosis but the binding of C1q together with IgG promoted the
binding of GBS to phagocytes (51).
Complement evasion by GBS
In addition to the capsule, several strains of GBS have been shown to
express other factors useful in avoiding of C activation on or near their
surface (Fig. 6).
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C5a-ase
The AP and CP C5 convertases cleave C5 into C5b and C5a, which is a
powerful chemotactic agent. In 1988 it was shown that a majority of GBS
strains were capable of directly inactivating C5a (139). The responsible
enzyme was called C5a-ase and it cleaves C5a and C5adesArg molecules
between the His and Lys present at amino acid positions 67 and 68 (38). C5a-
ase is believed to contribute to the pathogenicity of GBS. However, not all
invasive strains express C5a-ase so the production of this enzyme is not
necessary for virulence (5, 297). C5a-ase reduces the recruitment of
leukocytes to sites of infection and probably also contributes to GBS
virulence by preventing C5a from stimulating enhanced killing of the bacteria
by phagocytes (39, 139, 298).
Binding of factor H by GBS
Several strains of GBS serotypes Ia, Ib, II and V express the β protein (also
called Bac), which was originally identified by its capacity to bind IgA (271).
The β protein binds to the Fc part of serum IgA but not to secretory IgA
(191). The physiological basis for this is not clear. Recently, the β protein
was also shown to bind FH (11). The expression of β elicits the production of
protective antibodies (29).
Figure 7. A schematic structure of the GBS β protein. The regions known to
be needed for IgA and factor H binding are shown. The numbers indicate
amino acids at the start and end of regions. Abbreviations: S, signal peptide;
XPZ, the XPZ proline-rich region; C, C-terminal region.
The β protein is a 125 kDa surface protein (271). The N-terminal signal
peptide is followed by a region containing the IgA-binding site, consisting of
amino acids 153-225 (Fig. 7). The C-terminal half of the β protein contains a
region called XPZ, which consists of 30-50 repeats of a unique periodic
sequence in which every third amino acid is a proline (133). The size of the β
protein varies slightly between strains depending on the number of repeating
IgA binding region Factor H binding region
S XPZ C
  -37 +1 153 225  435  789 878  1097
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XPZ motifs (10). The actual role of the XPZ region is not known. Similarly
to pneumococcal Hic and M-proteins of GAS, the C-terminus of β is
anchored to the cell wall peptidoglycan via an LPXTG motif (133).
Sequence-based analysis of the secondary structure predicts that the β protein
is mainly α-helical except in the XPZ region (133). There are no cysteines in
the β protein which suggests a fibrillar structure. The β protein thus emerges
as an additional filamentous FH-binding protein on the surface of a gram-
positive coccus.
Neisseria meningitidis
Neisseria meningitidis (meningococcus) is a gram-negative aerobic
diplococcus belonging to the family of Neisseriaceae. Human beings are the
only natural hosts of meningococci. Meningococci cause sepsis and
meningitis, and more rarely, conjunctivitis, sinusitis, arthritis and pneumonia
(267). The annual incidence of meningococcal disease in the general
population is 1-3 per 100 000 in Western Europe and in the USA (319). In
Sub-Saharan Africa, in the so-called meningitis belt, the disease incidence
may reach 1 000 per 100 000 (319). Meningococci are spread by direct
mucosal contact and via aerosols for a distance of up to 1 meter (319).
Another pathogenic neisserial species is Neisseria gonorrhoeae
(gonococcus), the causative agent of gonorrhea. As with meningococci,
humans are the only natural hosts of gonococci. In addition to gonorrhea,
gonococci can cause conjunctivits, pharyngitis, arthritis and, rarely, a
systemic disease. Infection is transmitted by direct, usually sexual contact.
Neonates can be infected during birth. Most other neisserial species, e.g. N.
lactamica, N. sicca, N. cinerea and N. subflava, are commensal inhabitants
of the nasopharynx and very seldom cause disease.
Polysaccharide capsule
Meningococci are divided into 13 serogroups (A, B, C, E-29, H, I, K, L, M,
W135, X, Y, Z) according to the structure of their capsular polysaccharide.
Of the 13 serogroups, 5 (A, B, C, W135 and Y) cause over 90% of clinical
diseases (267, 319). Of these, serogroups B and C, and increasingly also Y,
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are the most important ones in industrialized countries. Serogroups A and C
dominate in Asia and Africa (319).
The expression of the polysaccharide capsule is a prerequisite for the
survival of meningococci in the circulation. The capsule offers protection
against C-mediated lysis and phagocytosis by neutrophils (170). The
polysaccharide capsule of serogroup B and C meningococci consists of
homopolymers of sialic acid (192). In group B meningococci, the sialic acids
are linked in an α-(2→8) manner to the linear polysaccharide (31). Similar
α-(2→ 8) linked oligomers of sialic acid have been identified in the
gangliosides of human fetal brain tissue (100). Therefore, serogroup B
polysaccharide is poorly immunogenic in humans (349).
The lipo-oligosaccharide of meningococci
The lipo-oligosaccharides (LOS) are major components of the
meningococcal outer membrane (Fig. 8). They resemble in structure the
lipopolysaccharide (LPS) of Enterobacteriaceae but lack the repeating O-
antigen-bearing polysaccharides and thus present the rough variety (279).
The LOS made by different species of Neisseriae are structurally similar.
The LOS contains a terminal lactosamine structure, lacto-N-neotetraose
(LNnT) (157). The α-2,3-sialyltransferase terminally links sialic acid to the
LNnT residue of neisserial LOS (113, 197, 198). Serogroup B and C
meningococci can sialylate their LOS endogenously, while gonococci
require exogenous sialic acid e.g. from blood or genital secretions (9, 198).
Outer membrane proteins
The principal outer membrane proteins of meningococci are divided into 5
classes (class 1-5) according to their apparent molecular weights (309).
Class 1 proteins
Class 1 proteins, together with the class 2/3 proteins, are porins, which are
the most abundant proteins present in the outer membrane of meningococci
(Fig. 8). Porins do not undergo antigenic shift during infection. However,
differences are seen between strains (20, 204). Porins are present in the outer
membrane of meningococci as trimers and function as pores (126). They are
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considered essential for bacterial survival as they modulate the exchange of
ions between the bacterium and the surroundings (126).
Class 1 protein or porin A (PorA) is an approximately 42 kDa product of the
porA gene (18). PorA has been proposed to consist of 16 transmembrane
regions and 8 surface-exposed loops protruding from the bacterial surface
(318). The transmembrane areas contain β-sheets which form a typical β-
barrel porin structure (74, 318). PorA is highly selective for cations (287,
308). The antigenic diversity among PorA is the basis for serosubtyping of
meningococci. However, the sequence variation is mainly confined to two
variable regions called VR1 and VR2, and the rest of the protein is highly
conserved (203). VR1 is situated on the first surface-exposed loop and VR2
on the fourth loop (318).
Figure 8. A schematic presentation of the meningococcal surface. Outer
membrane proteins are divided in five classes of which porins (class 1-3) are
the most abundant proteins.
Meningococcus is the only known neisserial species that expresses PorA.
Gonococcus has a porA gene, which, however, is not expressed (95). PorA is
expressed by most clinical isolates of meningococci but its level of
expression varies (314, 315, 317). The variability in expression is due to e.g.
point mutations in the coding region or even to the deletion of the gene (314,
315).
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Class 2 and 3 proteins
Class 2 and 3 proteins are encoded for by different alleles of the same gene,
p o r B  (141). Their expression is thus mutually exclusive, i.e. one
meningococcal strain expresses either class 2 (PorB2) or class 3 (PorB3)
protein. The primary structure similarity between PorB2 and PorB3 is 60-
70%. The average molecular weight for PorB2 is appr. 37 kDa and for
PorB3 34 kDa. Structurally, PorB consists of a similar β-barrel with
transmembrane regions and surface-exposed loops as PorA (215, 216, 318).
Interestingly, PorB3 is totally resistant to a number of proteases and
therefore it has been suggested that its surface-exposed loops are only
minimally exposed (215). PorB2 and PorB3 are homologous to the
gonococcal PorB1B and PorB1A, respectively (74). The interstrain antigenic
variation of meningococcal PorB is used to define serotypes of
meningococci.
Class 4 and 5 proteins
The class 4 protein is also called reduction modifiable protein (Rmp)
because its mobility in SDS-PAGE changes after reduction (from 24 to 32
kDa) (174, 195). It is highly conserved (99% sequence identity) in all
serogroups of meningococci and homologous to the gonococcal protein III
(174). Antibodies formed against the class 4 protein do not seem to be
bactericidal or opsonic against meningococci and structural studies indicate
that no substantial portion of class 4 protein is exposed on the microbial
surface (120, 265).
Class 5 proteins are trimeric in structure and their apparent molecular weight
is 27 kDa. They are subdivided into Opc and opacity (Opa) proteins. Both
Opa and Opc proteins are hypervariable and undergo antigenic shift even
during infection (4, 165, 306, 345).  A single strain may express no, one or
several class 5 proteins (292). Opa proteins are expressed by both
meningococci and gonococci. Instead, Opc proteins are expressed only by
meningococci (3). Both Opa and Opc proteins are involved in the attachment
of meningococci to epithelial cells in the early stages of disease (320, 321).
Pili
Gonococcal and meningococcal strains of Neisseriae express on their surface
filamentous structures that are called pili (291). Pili protrude through the
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capsule and mediate adhesion of the bacteria to epithelial and endothelial
cells (251, 290). MCP (CD46) has been shown to be the cellular receptor for
neisserial pili (167). Pili undergo phase variation and there are considerable
antigenic intra- and interstrain differences (306). Pili can also undergo
sequence variation during infection (273, 306).
Meningococcal vaccines
There is an efficient tetravalent polysaccharide vaccine against
meningococcal serogroups A, C, W135 and Y in clinical use. However, the
capsular polysaccharide of serogroup B consists of the α−(2→8) sialic acid
homopolymers, which are identical to the sialic acid on human fetal neural
tissue (99, 100). Thus, polysaccharide vaccines against serogroup B
meningococci are not immunogenic enough and vaccine research in this field
is concentrating on developing a protein vaccine against group B
meningococci.
Meningococcal disease
Meningococci frequently colonize the nasopharynx of healthy, asymptomatic
persons (7, 56, 116). Up to 20 to 40% of young adults are transient carriers
of meningococci (7). Small children are seldom meningococcal carriers.
Even though most contacts with meningococci lead only to an asymptomatic
carrier state, some people get a systemic, life-threatening infection. It is
estimated that only 1 % of people carrying a virulent strain get a
symptomatic meningococcal infection (56). The mortality rate of
meningococcal meningitis is 1-12% and of meningococcal sepsis 20-40%
(266, 319). About 20% of survivors suffer from permanent sequelae, e.g.
sensorineural deafness, mental retardation or have to undergo limb
amputation because of skin necrosis (83, 319). Half of the deaths occur in
the acute phase of the infection, during the first 24 hours after the onset of
symptoms (319). Meningococci can sometimes cause a persistent
meningococcemia with mild symptoms (319).
During infection meningococci release endotoxin within outer membrane
vesicles (OMV; also called blebs). OMVs consist of LOS, outer membrane
proteins, lipids and capsular polysaccharides (75). LOS is one of the major
factors that induces the host response during systemic infection. Endotoxins
induce pro- and anti-inflammatory cytokine production and activate the
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complement system, the contact system and the kallikrein-bradykinin system
(319). High cytokine concentrations correlate with the severity of the
developing shock (329). Both pro-inflammatory (e.g. TNF, IL-1β, IL-6) and
anti-inflammatory cytokines (e.g. IL-10, IL-12) are released.
Meningococcal disease is characterized by petechiae, pin-head sized
hemorrhages in the skin. In fulminant sepsis, the petechiae may coalesce into
large necrotic areas. Microscopically, these lesions consist of endothelial
damage, hemorrhages around small vessels and microthrombi in the vessels.
There is a major change in the permeability of the vascular endothelium due
to the inflammatory process induced by meningococci (171, 239, 245). This
leads to loss of fluid in the tissues, diminished venous return and,
consequently, the cardiac output falls. The compensatory vasoconstriction is
a contributing factor to thrombosis within the microvasculature. The
coagulation pathway is activated in meningococcal sepsis and the
anticoagulant and fibrinolytic pathways are not functioning properly, for
reasons not totally understood (42, 102). The plasma levels of the
anticoagulant proteins antithrombin, protein C and protein S are all reduced
(89). The dysfunction of the protein C activation pathway seems to be
critical in the development of thrombosis in meningococcal sepsis (86, 89).
The thrombotic events can ultimately result in tissue necrosis.
Complement and meningococci
The reasons why some individuals acquire a life-theatening meningococcal
infection and others remain carriers are still obscure. The difference does not
depend solely on the infecting strain, even though some strains are
considered to be more virulent than others. The host immune defense system
is one of the deciding factors why some individuals get an invasive
meningococcal disease while others remain asymptomatic carriers of the
pathogen.
The nasopharyngeal carriage of meningococci induces the production of
protective antibodies, even with some cross-protection between strains (115,
116, 259). Small children are rarely colonized with meningococci. However,
cross-protective antibodies can also be produced after contact with
apathogenic neisseriae, common commensal organisms of the oro-
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nasopharynx of children, or with antigenically cross-reacting enteric bacteria
(114, 118, 164).
The complement system is essential in the defense against meningococci.
Individuals deficient in the components of the alternative or terminal C
pathway are at an increased risk of acquiring neisserial infections. Unusual
meningococcal serogroups are often encountered in C deficient patients (96-
98, 268). It is estimated that individuals with deficiencies of late C
components have a 1000-10 000 –fold increased risk of meningococcal
infection and the recurrency risk is 50-60% (96). However, the mortality
rates for individuals deficient in late C components are lower than for the
normal population (96, 268). The milder course of disease is possibly due to
the fact that C activation could be responsible for many of the symptoms
during fulminant meningococcal disease. In contrast, properdin-deficient
individuals have a high fatality rate (30-50%) but only a low risk of recurrent
infections (96, 285). This difference is probably due to the importance of
MAC formation in the clearance of meningococci by the host immune
system.
Complement, however, plays a dual role in meningococcal infections. An
undisputed fact is that C is important in the defense against meningococci
but, on the other hand, C activation is partially responsible for the symptoms
during acute meningococcal infections (41, 129, 319). Complement
activation results in an increase of the anaphylatoxin C3a and C5a levels,
which in concert with activation products of the bradykinin system
contribute to the endothelial damage, vasodilatation and capillary leakage.
The level of C activation correlates with the severity of shock during
meningococcal infection and also with the plasma levels of LOS (41, 129). C
activation takes place not only on the meningococcal surface, but also on the
released OMVs. Thus, C activation does not effectively lead to bacterial
lysis. Lipopolysaccharides (and LOS) are potent activators of the C system
(76, 106). However, the meningococcal outer membrane proteins may be
even more potent C activators than meningococcal LOS (32). Both AP and
CP are involved in C activation (40, 129). However, the relative importance
of these pathways is not clear, nor do we understand how meningococci
evade C attack and manage to cause disease.
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Of the meningococcal C evasion factors, the capsule is thought to be the
most important. The capsule offers protection against C-mediated lysis and
phagocytosis by neutrophils (170). In group B meningococci, the capsule
consists of sialic acid and also LOS is endogenously sialylated (192, 198). In
gonococci, the sialylation of LOS correlates with serum resistance (341). In
1987, it was shown that both the sialic acid capsule and the sialylation of
LOS in serogroup B meningococci inhibited the activation of AP in vitro
(153). In 1994, Hammerschmidt et al. demonstrated that only LOS
sialylation contributed to the protection of group B meningococci against AP
activation (123). By comparing a group B meningococcus wild type strain, a
nonencapsulated mutant and a galE mutant where LOS is truncated and not
sialylated Vogel et al. argued that sialylation of both the capsule and LOS
are indispensable for gonococcal serum resistance (323). However, when
they used an lst mutant, which only lacks the terminal sialic acid of LOS, of
the same parental strain, they found that this mutation did not affect the
serum resistance of meningococci (322). Thus, in the presence of sialylated
capsule, the lack of terminal sialic acid of LOS is not critical but mutation
leading to the truncation of LOS (galE) is detrimental for the meningococcal
virulence. These, somewhat conflicting, data indicate that although
important factors have been identified on the surface of meningococci, the
mechanisms how they mediate C resistance have remained open.
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Aims
The general aim of this thesis work was to analyze factors that inhibit
complement by regulating the activities of the complement C3 convertases
on the surfaces of important pathogenic bacteria. The focus was on proteins
that bind soluble C regulators and help the bacteria to avoid C-mediated
opsonophagocytosis or direct lysis.
The specific aims were:
1. to examine the role of CRP as a regulator of complement activation
(I, II)
2. to characterize the interactions of the C regulator factor H with the
bacterial C evasion molecules: pneumococcal Hic and the group B
streptococcal β (II, III)
3 .  to study the complement resistance mechanisms of Neisseria
meningitidis (IV)
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Materials and Methods
The materials and methods used in this study are listed in Table 3 and are
described in more detail in the respective studies. The principal methods are
briefly described below.
Table 3. Laboratory methods used in studies I-IV
Methods Used in
Bichinonic acid (BCA) protein concentration
   determination assay I, II, III
Cloning and expression of SCR constructs III
Cofactor assay for C3b and C4b inactivation I, II, IV
Direct binding of radiolabeled proteins to microbes II, III, IV
ELISA for C activation and opsonization II
Flow cytometry analysis of opsonophagocytosis II
Iodine (125I) labeling of proteins I, II, III, IV
Microtiter plate binding assay I, II
Peptide mapping of binding sites III, IV
Opsonophagocytosis assay II
Radioligand binding assay II
Serum bactericidal assay IV
SDS-PAGE I, II, III, IV
Surface plasmon resonance analysis I, II, III
Abbreviations: SCR, short consensus repeat; ELISA, enzyme-linked
immunoadsorbent assay; C, complement; SDS-PAGE, sodium dodecyl
sulphate polyacrylamide gel electrophoresis.
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Recombinant FH constructs (Fig. 9) were used to localize the binding sites
for CRP and microbes on FH. The FH constructs were produced using the
baculovirus or the Pichia pastoris yeast expression system.
Figure 9. The recombinant constructs of factor H used in studies I-III. The
constructs used were produced using the baculovirus expression system
(SCR1-5, 1-6, 1-7, 8-20, 8-11 and 15-20) or the Pichia yeast expression
system (SCR11-15 and 12-14). All constructs have a poly-Histidine tag. The
heparin and C3b binding sites on FH and the constructs are marked. The
decay accelerating (DA) and cofactor (CA) activities of FH are located at the
N-terminal SCRs 1-4.
The surface plasmon resonance analysis (Biacore®2000 or Biacore®3000
equipment, Biacore AB, Uppsala, Sweden) was one of the main methods
used to study direct protein-protein interactions in studies I-III. The
appropriate proteins were coupled to the sensor chip flow cells and the
putative ligand was injected onto to the flowcell. The binding interaction was
monitored real-time and evaluated using the BiaEvaluation 2.0 or 3.0
software. The  surface plasmon resonance analysis was used to study CRP –
FH, pneumococcal Hic – FH and streptococcal β-protein – FH interactions
(I-III). The Biacore® equipment was employed for localization of the
binding regions on FH and for studying the effects of e.g. heparin on the
binding.
Factor H     
SCR1-7    
SCR8-20    
SCR8-11    
SCR11-15   
SCR12-14    
SCR15-20    
74 2 0
71
1 1 3
8 2 0
8 1 1
1 1 1 5
1 2 1 4
1 5
2 3 5 6 8 9 1 1 1 2 1 4 1 5 1 6 1 7 1 8 1 91 0
DA, CA
   C3b C3b/c C3b/d
Heparin binding site
1 3
1 3
1 3
2 0
SCR1-5    51
SCR1-6    61
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The pneumococcal strains were obtained from Dr. Lars Björck (Lund
University, Sweden), the group B streptococcal strains from Prof. Gunnar
Lindahl (Lund University) and the meningococcal strains from Dr. Sanjay
Ram (Boston University, MA, USA). The strains are shortly described in
Table 4 and in more detail in the respective studies (II-IV).
Table 4. Bacterial strains. A more detailed description of the strains used is
found in the respective studies.
Pneumococcal strains (study II)
HB565 encapsulated, Hic-positive
PR218 nonencapsulated, Hic-positive
FP13 nonencapsulated, Hic-negative
GBS strains (study III)
A909 type Ia, expressing β
∆bac β-negative mutant of A909
∆bac/pLZbac trans-complemented strain
Bac∆435-788 deletion mutant of β
Bac∆XPZ deletion mutant of β
Bac∆879-1064 deletion mutant of β
Meningococcal strains  (study IV)*
H44/76 wild type serogroup B, capsule +, LOS sialic acid +
H44/76 lst capsule +, LOS sialic acid -
H44/76 siaD nonencapsulated, LOS sialic acid +
H44/76 lst/siaD nonencapsulated, LOS sialic acid -
*In addition, PorA and PorB negative mutants of the above described four
strains were used.
Abbreviations: GBS, group B streptococci; LOS, lipo-oligosaccharide.
A direct binding assay using whole microbes and radiolabeled proteins was
used to analyze the binding of C components to microbes (II-IV). Microbes
were grown in appropriate broths, washed and the concentrations were
adjusted according to the assay used. FH, recombinant constructs of FH,
BSA, C4bp or recombinant constructs of C4bp were labeled with 125iodine
using the Iodogen method (274). Microbes were incubated with 125I-labeled
C components for 30 min at 37°C. After incubation, the microbe-protein
suspension was centrifuged through 20% sucrose to separate microbes and
microbe-bound proteins (pellet) from unbound protein (supernatant). The
sucrose tubes were quickly frozen and cut in two parts and radioactivities in
both parts were measured with the γ-counter. Binding was calculated as the
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percentage of bound radioactive protein (counts in pellet) vs. total counts
(pellet + supernatant). This binding assay was used to study direct binding of
FH, C4bp, BSA and recombinant constructs of FH and C4bp to microbes (II-
IV). The direct binding assay was also used to study the effects of heparin,
CRP, antibodies or unlabeled proteins on the binding of C components.
The C3b or C4b cofactor assays were used to study the effect of CRP on FH
function or the functional activity of microbe-bound C regulators FH and
C4bp (I-IV). FH acts as a cofactor for factor I-mediated cleavage of C3b,
and C4bp is a cofactor for factor I in the cleavage of C4b, and also of C3b
(104, 224, 243, 343). The effect of CRP on FH function was studied by
incubating FH, factor I and radiolabeled C3b in the presence of varying
amounts of CRP (I). After incubation the samples were run in an SDS-PAGE
gel under reducing conditions. Cleavage of C3b was detected by
autoradiography. To study the functional activity of surface-bound C
regulators, microbes were incubated with purified FH or C4bp or heat-
inactivated normal human serum (II-IV). After washing the microbes to
remove unbound proteins, factor I and C3b or C4b were added and the
incubation was continued at 37°C. Cleavage of radiolabeled C3b and C4b
was analyzed by SDS-PAGE and autoradiography. If the C regulator (FH or
C4bp) was bound to the microbial surface and not removed by washing, C3b
or C4b, respectively, should have become cleaved. In controls, the effect of
each of the reagents was tested by leaving them out from the incubation
mixtures.
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Results and Discussion
Regulation of alternative pathway activation by
CRP (I)
CRP is an acute phase reactant but its physiological role has remained
controversial. Is it required in antimicrobial defense or does it have a
homeostatic role during tissue injury and inflammation? CRP binds C1q and
activates the CP (325). However, CP activation by CRP does not lead to
activation of the terminal pathway (24). Instead, activation leads to the
deposition of C3b which is inactivated to iC3b. Previous studies have
suggested that CRP inhibits the AP activation, and it has been shown in our
laboratory earlier that CRP binds FH (12, 218). However, the functional
consequences of this binding had not been analyzed.
By using surface plasmon resonance and microtiter plate analyses it was
found that CRP indeed bound FH, and also, vice versa, FH bound to
immobilized CRP. With the help of recombinant fragments of FH, two
binding sites on FH were recognized: one at SCR7 and a second one within
SCRs 8-11. Due to the lability of the SCR11-15 fragment produced in the
baculovirus expression system, a third binding site within this region could
not be totally excluded. At the time of the experiments we unfortunately did
not have access to the Pichia expression system and the more stable middle
fragments of FH. The binding reaction between SCR7 of FH and CRP was
dose-dependently inhibited by heparin which suggests that the heparin and
CRP binding sites on SCR7 at least partially overlap. The binding between
SCRs 8-11 and CRP was less affected by heparin. The second heparin
binding site on FH is located around SCR13 and its nearness may affect the
interaction. CRP did not inhibit the cofactor activity of FH but it had a weak
inhibitory effect on the binding of FH to C3b.
These results can explain the previous findings of AP inhibition by CRP.
CRP binds to damaged cell membranes and activates complement by binding
C1q (325, 327). At the same time, there is a constant deposition of C3b on
the target. Factor H affinity for surfaces of injured cells may be diminished
by the loss of the integrity of the cell membrane and possible loss of
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glycosaminoglycans. Uninhibited C activation causes more inflammation
and more tissue damage. This vicious circle can be kept in control if CRP
acts as a linking bridge between the injured cell and FH (Fig. 10). Factor H
bound to CRP remains functionally active, regulates activation of the
amplification loop and C activation is inhibited at the C3b level. This is in
accordance with the earlier data that C activation initiated by CRP is stopped
at the C3b level (24).
Figure 10. The proposed function of CRP on surface of a damaged cell.
Both CRP and C1q are capable of binding directly to damaged cell
membranes. CP activation leads to the deposition of C3b on the surface. FH
and FHL-1 bind to CRP and the activation of the AP amplification loop is
inhibited and C3b is inactivated to iC3b. iC3b is recognized by the CR3
receptor of macrophages and the damaged cell is phagocytosed.
Abbreviations: FI, factor I; FH, factor H; FHL-1, factor H-like protein 1;
CR3, complement receptor 3; CP, classical pathway; AP, alternative
pathway.
CRP and C1q-initiated activation of the CP are presumed to be involved in
the removal of apoptotic cells (109, 214). According to our results and
previous results by others, the presence of CRP makes it possible for FH to
function. CRP binds directly to apoptotic cell membranes and enhances CP
activation on the cell surface but the presence of CRP prevents the assembly
of MAC (109). This function of CRP required the presence of C1q and FH.
When FH is available, C3b becomes inactivated to iC3b which is a ligand for
the macrophage CR3 receptor (Fig.10). It has been shown that binding and
phagocytosis via macrophage CR3-receptor do not cause leukotriene release
or a respiratory burst and can actually downregulate the production of IL-12
and interferon-γ by macrophages (6, 346, 352). Thus, the inflammatory
response is kept under control and excessive tissue damage can be prevented.
C1q
C3b
FHL-1
iC3b
CR3FH
C3b CRP
FI
FI
CP activation Suppression of AP activation                     and clearance
Macrophage
CRP
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We thus suggest that the main function of CRP is to focus the clearance
activity of CP and to restrict unncecessary tissue damage by  directing FH to
the site of injury and acting as link between FH and cell surfaces. Thereby, C
activation and focused waste clearance would be regulated without excessive
inflammation.
Pneumococci, group B streptococci and factor H
(II, III)
Pneumococci and GBS are pathogens of world-wide significance. In general,
in order for a microbe to be a pathogen, it needs to evade C activation.
However, the C evasion mechanisms of both pneumococci and GBS are still
incompletely understood. Some pneumococcal proteins have been shown to
have an effect on complement activation (PspA and PspC proteins and
pneumolysin) (152, 247, 313). The over 90 serotypes and the strain-
dependent variation within serotypes make it difficult to generalize findings
from one strain to other strains. Furthermore, pneumococci utilize phase
variation (336). The expression of several surface antigens depends on the
phase, whether colonizing or invasive (264). Many factors have been shown
to be important for virulence, and deletion of many of them has rendered the
pneumococci avirulent. However, several studies have convincingly shown
that the alternative and the classical pathway are of crucial importance in the
elimination of pneumococci, and the ability of pneumococci to evade
complement attack is probably one of the key reasons behind the
pathogenicity of this extremely important group of bacteria (50, 144, 150,
350).
The PspC-protein of serogroup 3 pneumococci (Hic) was shown to bind FH
and later Dave et al. showed that FH bound also to serotype 2 PspC but not
to PspA (70, 152). In both studies, the PspC-negative pneumococci did not
bind FH to their surfaces. Earlier, Neeleman et al. had shown that the
inhibition of complement activation and phagocytosis in serotype 3
pneumococci was mediated by binding of FH (229). Binding was inhibited
by trypsin pretreatment of the bacteria. Putative FH-binding proteins were
identified by immunoblotting experiments. The sizes of these proteins in
SDS-PAGE were 88, 150 and 196 kDa. As the sizes of PspC proteins vary
between strains, one of these bands could have represented PspC. Neeleman
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et al. also studied the FH binding to serotype 3 pneumococci by
immunoelectron microscopy (229). They detected two basic modes of FH-
binding to the pneumococcal cell wall. FH was seen either directly adjacent
to the outer surface of the cell wall or in association with projections
extending from the cell wall. The C3b degradation pattern observed by
Hostetter et al. on serotype 3 and 4 pneumococci is consistent with the
pattern observed when C3b is cleaved by factor I with FH as a cofactor
(146). Therefore, this degradation could be explained by FH-binding
proteins on the pneumococcal surface.
The interactions between pneumococcal Hic and factor H
The above findings warranted further studies on the interactions of
pneumococcal PspC proteins and factor H. We wanted to characterize the
Hic-FH binding reaction in more detail and also to study whether this
interaction had any significance for the pneumococcal virulence. For the
binding assays, we used Hic-positive and -negative pneumococcal strains,
recombinant Hic-GST and Hic proteins and recombinant fragments of FH.
Radiolabeled whole FH bound to Hic-positive pneumococci but not to Hic-
negative bacteria. However, even a stronger binding was seen using the
radiolabeled SCR8-20 fragment, while SCR1-7 did not bind to any of the
strains tested. The strong binding seen with SCR8-20 can be explained by
the better exposure of the Hic-binding sites on the SCR8-20 fragment than
on the whole FH, which has been proposed to have a convoluted structure
(13). The binding site on FH was further mapped to SCRs 8-11 and, later, a
second binding site was identified on SCRs 12-14. Using a microtiter plate
inhibition assay, we had concluded that the SCR8-11 site is the main binding
region. However, after obtaining the SCR11-15 and SCR12-14 recombinant
fragments of FH we could show with surface plasmon resonance analysis
that there is also this second, but a weaker binding site for Hic on FH.
Also CRP binds to the SCR8-11 region but CRP did not affect the binding of
SCR8-20 to Hic-positive pneumococci. Interestingly, however, CRP
increased the binding of SCR8-20 to Hic-negative pneumococci in the
presence of calcium. Thus, it seems that by binding to the pneumococcal C-
polysaccharide, CRP can act as a link between PspC-negative pneumococci
and FH. In this way, pneumococci could have a double mechanism to evade
AP activation – direct binding of FH via the PspC protein and non-direct
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binding of FH by using CRP as a linker. It was shown in the early 1980’s
that CRP increased the interaction of FH and C3b on pneumococcal surface
and the AP activation was thus suppressed (218, 219). The fact that
phosphorylcholine in pneumococci is usually hidden underneath the capsule
means that CRP may bind more avidly to damaged pneumococci than to
viable bacteria (72). We also tested the effect of phosphorylcholine on the
SCR8-11 – CRP interaction. Phosphorylcholine (10-1000 µg/ml) did not
inhibit the binding CRP to SCR8-11 (Jarva et al., unpublished). This
suggests that CRP can bind to both pneumococci and factor H at the same
time.
Functional activity of pneumococcus-bound factor H
In the C3b cofactor assay, the ability of the Hic-bound FH to act as a
cofactor for factor I-mediated cleavage of C3b was studied. Even when the
concentration of FH in the reaction mixture was as low as 0.1 µg/ml
(compared with the serum level of 500 µg/ml), Hic-positive pneumococci
were able to bind enough FH on their surfaces for C3b to become cleaved.
The same could be seen using 0.5% serum. The cofactor activity seen after
incubation of the bacteria in serum was inhibited by polyclonal anti-FH
antibody, suggesting that the cofactor activity seen was explicitly due to FH.
Using an ELISA assay, we could confirm that C3b became more efficiently
inactivated to iC3b on Hic-positive pneumococci, again indicating the
functional activity of FH bound to Hic. The effect of Hic on the ability of
pneumococci to evade opsonophagocytosis was studied by FACS and by
immunofluorescence microscopy by counting the number of pneumococci
phagocytosed by polymorphonuclear leukocytes (Fig. 11). Hic-negative
pneumococci were phagocytosed more readily than Hic-positive
pneumococci. Thus, we postulate that the Hic-FH interaction is a C evasion
and virulence mechanism of pneumococci.
Even though there is considerable strain-dependent variation between PspC-
proteins, the initial studies by Janulczyk et al. showed that pneumococcal
strains of several serotypes bound FH (152). Also, the results of others
showed that at least serotype 2 PspC protein was also capable of binding of
FH, and that the binding region on FH is located to SCRs 13-15 (70, 81). We
have also screened dozens of clinical strains and found putative FH-binding
proteins in most invasive pneumococcal strains (Jarva et al., unpublished).
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We can not, of course, exclude that pneumococci express several FH-binding
proteins. So far, however, FH-binding has been shown only for PspC.
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Figure 11. The effect of Hic on the opsonophagocytosis of pneumococci.
Equal amounts of Hic-positive (strain PR218) and Hic-negative (FP13)
pneumococci were incubated with 0-25% normal human serum and then
with freshly isolated polymorphonuclear leukocytes (PMN). The cells were
washed and transferred to object slides using a cytospin centrifuge. The
slides were stained either with acridine orange or gram-stain and the number
of attached/ingested bacteria per the number of PMN was counted.
The use of PspC-family proteins as vaccines
The PspC protein family is so polymorphic that it may not seem like an
optimal vaccine candidate. However, the variability between proteins is
generated by the eight building domains within the N-terminal part of the
molecule (147). Brooks-Walter et al. showed that immunization of rabbits
with recombinant PspC elicited cross-protective antibodies also to PspA and
conferred immune protection against pneumococcal bacteremia (49). The
use of PspC as a vaccine needs further studies. In principle, inhibition of the
interactions between PspC proteins and factor H by vaccine-induced
antibodies could sensitize the respective pneumococci to complement-
mediated opsonophagocytosis.
Characterization of the factor H – β protein interaction
Interestingly, the C-terminal region of the β protein from GBS which was
recently shown to bind FH shows some homology to Hic and other PspC
proteins (Fig. 2 in III). The β protein was originally identified as an IgA-
binding protein expressed by many strains of GBS (191, 271). On β, the
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binding site for IgA has been located to a 73-amino acid region in the N-
terminal half of the protein (133, 158). In contrast, the factor H-binding
region was tentatively located to the C-terminal half of the β protein (11).
Recently, the genome of serotype V GBS was published (301). Gene synteny
conservation was more marked between GBS and GAS than between GBS
and pneumococci. Despite the relatedness of GAS and GBS genomes, there
is no structural homologue for the β protein in GAS.
Knowing that Hic and the β protein are structurally related and both bind
FH, we wanted to compare the FH-binding characteristics of these bacterial
proteins. We studied the binding of FH and recombinant fragments of FH to
GBS strains expressing and not expressing β and also a set of strains where
mutations in the β protein spanned the C-terminal region i.e. amino acids
435-1097. Binding studies were also performed with the purified β protein.
Using a direct binding assay and surface plasmon resonance analysis, the β
binding site on FH was mapped to SCRs 8-11 and to SCRs 12-14, i.e. to the
same sites where Hic was found to bind earlier. The binding of the β protein
to SCR11-15 was only weakly inhibited by heparin. In order to study
whether Hic and β bind to overlapping sites on FH, we tried to look at the
possible inhibitory effect of β on the binding of SCR8-11 and SCR11-15 to
Hic. However, due to the small amounts of protein we were able to reach
only equimolar concentrations of β  and of the FH fragments, and no
inhibitory effect at this level could be seen. Thus, whether Hic and β bind to
overlapping or only nearby sites in the middle region of FH remains
uncertain. However, the slight differences in heparin inhibition suggest that
the binding sites may differ in structure.
Localization of putative factor H-binding sites on the β protein and Hic
To localize the FH binding site on the β protein the GBS strains expressing
mutants of β  were used in direct binding assays to test the ability of
radiolabeled SCR8-20 to bind to the bacteria. The primary binding region on
the β protein was within amino acids 435-788, as the deletion of this region
in β almost totally abolished the binding. A peptide spot analysis was used to
further map putative binding sites on the β protein and also on Hic. For this
analysis, we chose the regions in β and Hic known to be needed for FH
binding. We could identify 5 putative binding sites for FH on β and 3 on
Hic. Some of these sites are in the homologous regions of Hic and β. As the
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3D-structures of these proteins have not been established yet, we can not be
certain whether these regions come close together in the final conformation
or whether they possibly are separate sites on a filamentous protein.
However, based on computer analysis of the predicted secondary structures,
both Hic and β are mainly of α-helical structure (133, 152). Also, there are
no cysteine residues in Hic or β so no disulphide bridges can be formed.
Therefore, it is probable that both proteins have a fibrillar or filamentous
structure. If so, the FH-binding sites on β and Hic would be distributed along
the filament. Thus several binding interactions between FH and β or Hic
could take place and lead to enhanced avidity between FH and the microbial
proteins.
Even though both GBS and pneumococci are classified as streptococci, the
disease spectrum caused by them differs, and they represent distinct bacterial
species. The result that Hic and β, proteins from two different bacterial
species bind FH in an analogous manner, is a novel finding. This suggests
that the expression of these FH-binding proteins has been conserved through
evolution and that binding of FH is an important characteristic for the
microbes in order to survive in the human host.
The use of the β protein as a vaccine
Analogously to pneumococcal PspC proteins, the β protein emerges as an
attractive vaccine candidate. Antibodies directed against β would promote C
activation and opsonophagocytosis and inhibit the acquisition of the C
regulator FH onto the GBS surface. The β protein has been tested in a
conjugate vaccine composed of GBS type III capsular polysaccharide
coupled to β, which is not expressed by type III GBS (196). This vaccine
elicited protective antibodies against the type III capsular polysaccharide and
the β protein in mice. However, the β protein conjugate vaccines have not
yet been tested in clinical trials.
Factor H (I-III)
Our studies on the interactions of CRP with factor H and the C evasion
mechanisms of pneumococci and GBS led to the recognition of a novel
binding region in the middle of FH. Previously, the SCR8-11 region of FH
had no known ligands. Microbes have been shown to bind to SCR7 (M-
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proteins of GAS, C. albicans) and to the C-terminus (OspE of B. burgdorferi,
C. albicans and gonococcus) of FH (33, 136, 212, 254). All the three FH-
ligands characterized in this study (CRP, Hic and β) had two binding sites on
FH (Fig. 12). The presence of multiple binding sites on the extended structure
of FH also emerges as a new concept from this study. It is likely that multiple
binding sites ensure a high binding avidity. Since also the microbial proteins
have elongated structures (possibly coiled-coils) one can envisage that the
binding partners align longitudinally with each other.
Figure 12. CRP, Hic and β-protein binding sites on factor H recognized in
this study. The three binding sites for C3b and for heparin (++) are marked
above the circles that represent the 20 SCR domains of factor H.
C4bp and meningococci (IV)
Neisseria meningitidis is an important and feared cause of meningitis and
sepsis. In industrialized countries, serogroup B is one of the most common
serogroups isolated (267, 319). Mass vaccinations are not a practice and the
present vaccines in use, which are all directed against capsular
polysaccharides, are not protective against serogroup B meningococci. This
is due to the poor immunogenicity of serogroup B capsular polysaccharide.
The latter has structural homology with fetal neural tissues in humans (99,
100). Therefore, the goal now is to develop vaccines directed against non-
capsular antigens of meningococci. Thus, the non-capsular meningococcal
virulence factors are of significant interest.
Complement is essential in the host defense against meningococci. This is
underlined by the fact that individuals deficient of AP or terminal pathway
components have an increased risk of recurrent meningococcal infections
(96). Deficiencies of the CP components do not usually predispose to
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neisserial infections. It seems that AP is needed to reject meningococci while
meningococci themselves are able to avoid CP. Therefore, we wanted to
examine the mechanisms by which meningococci evade CP activation. It had
previously been shown that both the AP and CP were activated in
meningococcal infection but the relative importance of the pathways is under
dispute and probably depends on several factors.
Binding of C4bp to meningococci
Initially we looked at the direct binding of radiolabeled C4bp to 12 randomly
chosen clinical isolates of meningococci representing serogroups A (n=2)
and B (n=10). The binding of C4bp to the bacteria varied between 12 and
45% under the conditions used. This warranted further studies of the role of
C4bp in C evasion by meningococci. Our aim was to locate the binding site
for C4bp on the meningococcal surface, and to study whether this binding
interaction has any significance in the survival of meningococci in humans.
We used 12 serogroup B meningococcal strains with deletions or
combinations of deletions of the capsule, LOS and the major outer
membrane proteins PorA and PorB. In addition, we had C4bp purified from
human plasma, recombinant C4bp with deletions of SCR domains and
monoclonal antibodies raised against C4bp. By using the direct binding
assay with radiolabeled C4bp we found that deletion of PorA significantly
reduced the binding of C4bp to meningococci. Deletion of LOS had no
effect on the binding, but the deletion of the polysaccharide capsule
enhanced the binding of C4bp to meningococci. The capsule probably
presents a steric hindrance, thus its removal increases the binding of C4bp to
proteins underneath. The binding of C4bp to strains expressing both PorA
and PorB increased from 19% to 38% when the capsule was deleted.
However, in the absence of capsule, the binding of C4bp to the PorA-
negative strain was also markedly increased to 21% compared to the 4%
binding to the encapsulated strain. Thus, our data suggests that PorA is
necessary for the binding, but there may be other factors involved which are
exposed when the capsule is removed. These factors, however, are of
questionable physiological significance since nonencapsulated
meningococcal strains are only very rarely isolated from clinical samples.
The capsule is thus considered a prerequisite for virulence.
The binding of radiolabeled C4bp to meningococcal strains was dose-
dependently inhibited by heparin and unlabeled C4bp but not by BSA. The
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results from the direct binding assays using recombinant mutants of C4bp
with deletions of single SCR domains and from the inhibition assays with
heparin and monoclonal antibodies suggested that the binding site for
meningococcus on C4bp is located in SCRs 2 and 3 of the α-chain. The
C4bp binding sites for heparin and C4b have been located to the α-chain
SCRs 1-3. Thus, a critical question was whether the C4bp bound to
meningococci could still bind C4b and exert its C regulatory functions. This
was studied by the cofactor assays in which we examined the ability of
meningococcus-bound C4bp to act as a cofactor for factor I in the cleavage
of C4b and C3b. Indeed, meningococcus-bound C4bp was functionally
active and both C4b and C3b became cleaved in the presence of factor I.
This can be explained by the fact that C4bp has 7 α-chains, each of which
functions individually. Whether a single α-chain of C4bp can bind
simultaneously both C4b and meningococcus remains to be studied with
monomeric constructs of the α-chains.
We used serum bactericidal assays to further confirm the physiological
significance of the interaction between serogroup B meningococci and C4bp.
These assays, however, are problematic as meningococci also bind FH and
the deletion of PorA does not markedly affect the FH-meningococcus
interaction (253, Jarva et al., unpublished). The approach was to compare the
serum resistance of a strain expressing both PorA and PorB with a strain
where PorA had been deleted. These pairs differed in their ability to bind
C4bp but not FH. The PorA-positive strain survived better in 1%, 3% and
10% serum than the PorA-negative strain (Fig. 6 in IV and unpublished). For
example, by using 10% serum, 25% of PorA-positive vs 87% of PorA-
negative bacteria became killed at 60 minutes. This was most clearly seen
with the strains not expressing LOS, which presumably is one of the binding
targets for FH. Thus, C4bp-binding seems to play an important role in the C-
evasion of meningococci.
Meningococcal PorA – C4bp interaction
On the basis of experiments using deletion mutants of meningococci, the
putative target molecule for C4bp binding is PorA. To verify the C4bp-PorA
interaction it would be necessary to directly demonstrate a protein-protein
interaction. However, because PorA is an integral membrane protein (a
porin) with 8 extracellular loops and 16 transmembrane segments, it is
difficult to study the interaction directly at the protein level.
62
Our preparations of purified PorA and PorB were in a detergent solution, and
could therefore not be used in the surface plasmon resonance analysis. Also,
no binding of radiolabeled C4bp to PorA (or PorB) run into an SDS-PAGE
gel and transferred to a nitrocellulose membrane could be detected. These
results suggest that the binding of C4bp to PorA is dependent on
conformation and proper orientation of the PorA protein on the outer
membrane of the meningococcus.
In another approach, we used a peptide spot analysis with peptides
representing the surface-exposed loops of meningococcal PorA and PorB
and, for comparison, gonococcal Por1A and Por1B. Radiolabeled C4bp
bound most strongly to PorA peptides representing loops 1 and 4, i.e. the
variable loops (Fig. 13). The most prominent binding regions contained
positively charged residues, lysines and arginines. However, the putative
region on loop 4 was rich in alanine and valine, small hydrophobic amino
acids. On the meningococcal surface, PorA forms trimers in which loops of
each molecule come into contact with each other. Therefore, depending on
the 3-dimensional conformation of the loops in the porin trimer, the putative
binding sites could form 1-6 ligand sites for C4bp. The avidity of the binding
interaction is further increased by the redundancy of binding sites on C4bp
as each of the seven α-chains could bind to PorA independently.
PorA and meningococcal vaccines
Based on our current data and previous data from elsewhere, PorA emerges
as an important virulence and C evasion factor of serogroup B
meningococci. PorA has been a candidate in the development of
meningococcal vaccines. Antibodies directed against PorA and PorB are
produced after meningococcal infection (121, 122). In an animal model, only
the bactericidal antibodies against PorA were protective against bacterial
challenge (276). However, the expression of PorA is variable, although no
antigenic variation during infection has been detected. Occasionally,
meningococcal strains not expressing PorA have been isolated from clinical
samples, and recently an epidemic (7 cases) with group C meningococci not
expressing PorA was described (316). The sequence of PorA varies between
strains but the variation is mainly confined to two surface-exposed loops, 1
and 4 (203). In our peptide spot analysis, the main binding region for C4bp
appeared to be located on loop 1 and a secondary site was on loop 4.
Interestingly, the main binding site on loop 1 was outside the variable area
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(Fig. 13). Therefore, antibodies against this conserved region of PorA could
inhibit the binding of C4bp to the meningococcal surface and allow CP
activation. Thus, our findings have potential significance for protein vaccine
development against meningococci.
 Loop
1  2 3  4 5 6 7 8
Figure 13. Folding model of PorA of serogroup B meningococcus H44/76.
The top part of the model shows the surface-exposed loops, and the central
part represents the transmembrane segments. The hypervariable regions in
loops 1 and 4 are boxed. Bold letters: a putative C4bp binding site on loop 1.
Amino acid residues in the transmembrane segments are shown alternating
where they can form a β strand. Adapted from (318). Printed with the
permission of the American Society for Microbiology.
C4bp – protein S complex and the pathogenesis of meningococcal
disease
Fulminant meningococcal sepsis is characterized by hemorrhages,
thrombosis in small vessels and, ultimately, disseminated intravascular
coagulation. Procoagulant pathways are activated but the anticoagulant
pathways are impaired (245). The plasma levels of the anticoagulant proteins
antithrombin, protein C and protein S, and also of C4bp are reduced in
meningococcal sepsis (89, 129). Endothelial damage and loss of endothelial
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glycosaminoglycans, thrombomodulin and protein C receptor contribute to
the dysfunction of the anticoagulant pathways (89, 171, 239).
As much as 70% of the anticoagulant protein S is in complex with C4bp and
functionally inactive (66-69). Based on the results of this study,
meningococci bind C4bp both with and without protein S. We don’t yet
know how much this affects the plasma levels of C4bp or whether the
reduction of C4bp plasma levels is simply due to consumption of C4bp
because of CP activation. Another question is whether the meningococcus-
C4bp interaction has an impact on the plasma levels of free and active
protein S. C4bp levels increase during the acute phase reaction (105, 288).
During infection, more C4bp is released to circulation and complexed with
protein S, whose production may not keep up with the rate of C4bp
production. Therefore, the amount of free and active protein S would be
decreased, and thus contribute to the dysfunction of the anticoagulant
pathway. The possible effects of the meningococcus-C4bp-protein S
interactions on the development of the severe disseminated intravascular
coagulation syndrome typical for fulminant meningococcal sepsis warrant
further studies.
Complement evasion in vivo
Animal models have been used to study the importance of CRP in the
protection against pneumococcal infections and the virulence and C evasion
mechanisms of pneumococci, group B streptococci and meningococci.
However, CRP, which binds both pneumococci and factor H, is not an acute
phase reactant in mice (175, 248). Models utilizing mice transgenic for
human CRP are not necessarily relevant until it is shown that human CRP
binds mouse C1q and factor H similarly as respective human proteins. Thus,
the data concerning the role CRP in protection against pneumococcal
infections obtained from the mouse models can not be extended to humans
as such.
The results of current (II-IV) and earlier studies show clearly that C
regulators are involved in the C evasion by pneumococci, GBS and
meningococci. Mouse and rabbit models have been used in studies on
pneumococci, and the infant rat model is widely used in meningococcal
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immunization studies. However, a major disadvantage of these models is that
the mouse, rabbit or rat C regulators may not behave similarly as the human
C regulators and the binding of microbial proteins to these regulators could
be species specific. For example, we could not detect binding of FH from
mouse serum to pneumococci nor the binding of C4bp from rat serum to the
wild type serogroup B meningococcal strain used in our studies (Jarva et al.,
unpublished). Thus, conclusions drawn from immunization studies and the
role of complement evasion in animal models need to be treated with
caution.
Complement evasion by pathogenic microbes (II-IV)
As has become apparent from the above, many pathogenic microbes utilize
binding of C regulators for their own benefit. In general, microbial surfaces
represent activator surfaces for the AP of C, and activation of C on them
continues without restriction. By offering binding sites for factor H or C4bp
the microbe can transform its role as a target C activator to a nonactivator
(Fig. 14).
Figure 14. Bacterial evasion of complement by binding factor H. The
pneumococcal Hic and B streptococcal β protein are predicted to have
extended structures that project out from the cell wall. Both proteins bind
FH. Factor H acts as a cofactor for factor I (I) and C3b becomes inactivated
to iC3b both on the bacterial surface and in the nearby fluid-phase. Without
Hic or β, FH would not bind to the bacterial surface and C activation would
continue.
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Conclusions and Summary
Complement has a role in the immune defense against invading microbes as
well as in the clean-up of the body. CRP is a complement-related molecule
involved in both roles. Many of CRP’s functions are exerted through
activation of the CP. However, while CRP activates the CP, it also regulates
C activation at the C3b level via recruitment of FH. The structure of CRP (a
pentraxin) has remained conserved through evolution. It is ubiquitous among
mammalian species and no deficiencies are known. Microbial structures
constantly evolve in response to host immune defense. If the main role of
CRP was in the defense against microbes, it would require a capacity to
adapt to changing invaders. The conservation of CRP suggests that its
primary function is not in host defense but in host clean-up. In this function,
CRP collaborates with complement. CRP binds to apoptotic cell membranes,
activates the CP and binds FH to prevent C activation beyond the C3b stage.
Upon the recruitment of FH, C3b becomes inactivated to iC3b, which is
recognized by the CR3 receptor (CD11b/18) on phagocytes. Activation of
CR3 leads to an anti-inflammatory type cytokine response, whereby an
excessive inflammatory reaction and tissue damage is avoided. Results of
this study thus support a new view of a purposeful role of CRP in the
response to injury. CRP also reacts with pneumococci, but this is considered
to be a secondary function. In fact, pneumococci could themselves utilize FH
for their own benefit to avoid C attack.
The exploration of the virulence mechanisms of microbes helps us to
understand how microbes evade the host’s immune defense and learn more
about immune mechanisms of the host. Ultimately, this will also help us to
prevent infections. Microbes have survived on earth for over 3 billion years.
Since the emergence of animal hosts the microbes have had a long time to
develop ways to evade the immune defense mechanisms of their potential
hosts. The C evasion mechanisms of pneumococci, GBS and meningococci
examined in this study are analogous, yet different from one another.
Serotype 3 pneumococcal Hic and group B streptococcal β protein bind the
middle part of FH. Via the actions of surface-bound FH the bacteria are
subsequentely able to avoid opsonophagocytosis. PorA surface protein of
serogroup B meningococci seems to be required for binding of functionally
active C4bp. Thus, we conclude that the binding of C regulators, either the
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AP inhibitor FH or the CP inhibitor C4bp, constitutes an important virulence
mechanism of these three bacterial species.
In the course of the above described studies we identified three new ligands
for SCRs 8-11 on FH. This region of FH has previously been considered
“silent”, with no known ligands or C regulatory functions. The results show
that SCRs 8-11 have binding sites for CRP, pneumococcal Hic and B
streptococcal β, and none of these ligands interferes with the C regulatory
functions of FH. This middle region thus emerges as a novel functional
region of FH.
One particular aspect in studying microbial evasion of complement and
immune attack is the development of vaccines. The goal is to develop
protein or conjugate vaccines, which would be immunogenic in infants,
adults and in the elderly. The vaccines should elicit cross-protective
antibodies. The complement evasion molecules of pneumococci, GBS and
meningococci could be ideal protein components in conjugate vaccines. This
is because the antibodies directed against the complement-binding proteins
would not only recognize an outer surface component but they could also
neutralize a virulence property.
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